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2
meet or surpass the requirements described in ISO 5833
Implants for Surgery—Acrylic Resin Cements.
PMMA was first used in orthopedic surgery by Sir John
Charnley for total hip arthroplasty in 1970 and the current
formulation is essentially unchanged. Bone cement has dif
ferent properties than other PMMA resins, due to both its
additives and how it is prepared. Although the fully polymer
ized form of PMMA has good compatibility with human

BOMATERAL COMPOSITIONS
CROSS-REFERENCE TO RELATED
APPLICATIONS

This application is based on and claims priority to U.S.
Non-Provisional Application Ser. No. 61/456,045 filed on
Oct. 29, 2010, which is hereby incorporated herein by refer
CCC.
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STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH

This invention was made with government Support under
Department of Defense/USA Medical Research AQCAward
No. W81XWH. The government has certain rights in the
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invention.
FIELD OF THE INVENTION

This invention relates in general to compositions of matter
and more particularly, to compositions useful as biomaterials.
The compositions comprise organosilicon monomers (pref
erably silorane monomers) and chemical curing systems or
dual chemical/light curing systems. The compositions may
include one or more tetraoxaspiro5.5undecanes (“TOSUs)
and/or fillers. Photoacids, photosensitizers and/or a reaction
promoters (electron donors) may also be included in the com
position. The polymerizable compositions of the present
invention are useful for a variety of applications, including
use as biomaterials, for example as bone cements, bone sta
bilizers, dental composites, crowns, and the like.
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DESCRIPTION OF RELATED ART

35

Bone fractures are suffered by nearly six million Ameri
cans each year. The common methods for fracture stabiliza
tion Such as casts, splinting, intramedullary pinning, and
external fixation, do have their drawbacks especially with
regards to stabilization of Small and growing bones. In addi
tion to hampering soft tissue management, splinting cannot
adequately stabilize highly unstable fractures or injuries with

40

considerable bone loss. There must be sufficient bone cortex

to support pin stabilization, especially with epiphyseal (near
the end of the bone) fractures. These fractures lacking suffi
cient cortex often require pin placement across the adjacent
joint leading to joint stiffness. Fractures in children can be
further complicated by rapid growth of bone, thus requiring
continual adjustment of the stabilization technique.
Frequently, bone cement has been used to stabilize frac
tures. The current bone cements are methacrylate based sys
tems packaged in two components. The powder contains a
mixture of polymethyl methacrylate (“PMMA'), methyl
methacrylate-styrene-copolymer, and a radio opacifier (either
barium Sulfate or Zirconium oxide). The second component is
a liquid monomer typically containing methyl methacrylate,
N,N-dimethyl-p-toluidine, and hydroquinone. The cure time
of commercially available PMMA bone cements ranges from
6 to 22 minutes, and reaches a peak exotherm from 75 to 110°
C. Thermal finite element models have found temperatures in

component is antigenic and induces severe toxicity, contrac
tion with polymerization, and intense heat generation. These
cements are highly exothermic, and have been shown to cause
thermonecrosis in animal models. Bone cement typically has
Voids due to Volatilization of the monomer during polymer
ization, which results in a porosity of 3 to 11%. Pressurization
of the resin, as occurs during implantation of a femoral bone,
can raise the boiling point of the monomer and decrease pore
formation and size, but can be problematic if air is carried into
the resin during implantation. The volume contracts by 5-7%
during polymerization. This causes internal pores which can
serve as crack initiators. The heat generated is determined by
thickness/weight of resin, with a peak temperature rise in the
range of 75-85°C. Although PMMA is biologically compat
ible, the monomer is an irritant and possible carcinogen.
Unreacted residual monomer, approximately 3% after one
hour, is present in the hardened polymer and can affect
strength while leaching out into tissues, potentially causing
hypotension, a common problem which can lead to possible
cardiopulmonary events. The bone-resin interface is achieved
by mechanical interlock, because the PMMA has no inherent
adhesive properties. Dense bone causes less resin penetration,
which can be an issue for resin fixation in younger patients
Such as military recruits whose bone structure may have less
trabecular porosity. Use of bone cement in hip arthroplasties
has also been shown to increase systematic levels of gamma
glutamy transperptidase (“GGTP), which can result in anor
exia and nausea/vomiting. Other drawbacks to the use of
PMMA-based cements include lack of bioactivity, volumet
ric shrinkage upon polymerization, toxicity of the activator
(N,N-dimethyl-p-toluidine) and possible involvement of the
radiopacifier in third body wear. Therefore, it would be desir
able to provide an alternative bone cement to PMMA-based
Cement.
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BRIEF SUMMARY OF THE INVENTION
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excess of 60° C. at the bone cement and cancellous bone

interface. The fracture toughness of bone cements generally

ranges from 1.0 to 1.5 MPalm’. Flexural strength of bone
cements ranges from 60 to 75 MPa and flexural modulus is
between 2.2 and 3.3 GPa. Bone cements typically have a
tensile strength of 50 to 60 MPa. These property values all

tissue, there are several drawbacks to its use. The monomer
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The present invention is directed to biomaterial composi
tions, as well as methods for manufacturing the same, and
methods of using the compositions. The biomaterial compo
sition comprises one or more organosilicon monomers (such
as a silorane) and a chemical curing system or dual chemical/
light curing system for polymerizing the monomer(s). The
compositions may include one or more tetraoxaspiro5.5
undecanes (“TOSUs) and/or fillers. Accelerators (such as
photoacids), photosensitizers, and/or electron donors may
also be included in the composition as appropriate.
The biomaterial compositions of the present invention are
comparable to or superior to conventional PMMA systems in
many characteristics. For example, in one aspect of the
present invention, the compositions of the present invention
exhibit significantly less polymerization stress without an
associated proportional reduction in mechanical properties.
In another aspect of the present invention, the biomaterial
compositions exhibit enhanced biocompatibility and reduced
cytotoxicity and genotoxicity. In general, the compositions of
the present invention will not generate the cytotoxicity, anti

US 9, 186,302 B2
3
genicity, polymerization stress, and heat generation that are
characteristic of conventional PMMA bone cements.

In another aspect, it is anticipated that the biomaterial
compositions of the present invention exhibit a peak exo
therm below 50° C., more preferably below 45° C. For
example, the silorane-based compositions of the present
invention may exhibit a peak exotherm below about 49, 48,
47, 46, 45, 44, 43,42, 40,39,38, 37, 36,35,33, 32, 31, or 30°

C. Most preferably, the peak exotherm is within 1, 2, 3, 4, or
5°C. of the body temperature of the patient. For example, the
P1 system (chemical curing system) and P2 systems (dual
chemical/light curing system) described herein typically
exhibit a peak exotherm of about 25 to 30°C. As such, it is
anticipated that the biomaterial compositions of the present
invention will not cause thermal necrosis.

The low exotherm of the chemically or dual cured silorane
biomaterial (about 25- to 30°C.) compared to commercially
available bone cement (about 70 to 90° C.) is an important
property of the compositions of the present invention. Many
antimicrobial agents and growth factors exhibit heat sensitiv
ity. For example, proteins are degraded or denatured with
increasing heat leading to inactivation or conversion to com
pounds with potential toxicity. Even antimicrobial agents
such as silver (though relatively heat insensitive) may exhibit
Some heat sensitivity in certain crystalline forms. Impor
tantly, conventional bone cements have not included growth
factors (such as bone morphogenetic protein 2) due to their
thermal instability. See Prountos et al., The effect of antibiot
ics on bone healing current evidence, Expert Opin Drug Saf.
10935-945 (2011); Yano et al., Osteoinductive capacity and
heat stability of recombinant human bone morphogenetic
protein-2 produced by Escherichia coli and dimerlized by
biochemical processing, J Bone Miner Metab 17 355-363
(2009); and Landry et al., The kinetics of thermal instability in
nanocrystalline silver and the effect of heat treatment on the
antibacterial activity of nanocrystalline silver dressings, Bio
materials 30 6929-6939 (2009). With the lower exotherm of
the silorane biomaterial compositions of the present inven
tion, antimicrobials and growth factors (such cartilage or
bone growth factors, e.g., cartilage-derived morphogenic pro
teins or bone morphogenic proteins) should remain stable. In
one aspect, the biomaterial composition contains growth fac
tors selected from the group consisting of TGFB1, TGFB2,
TGFB3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7,
BMP-8, BMP-9, CDMP-1, CDMP-2, or CDMP-3.

In another aspect, the biomaterial compositions of the
present invention exhibit flexural strength greater than about
20 MPa, and preferably greater than about 50 MPa. For
example, the flexural strength may be greater than about 20,
30, 40, 50, 55, 60, or 65 MPa (or have a value of some range
therebetween), with higher flexural strengths being preferred.
For example, the P1 system (chemical curing system) typi
cally exhibits a flexural strength of about 22 to 33 MPa, and
the P2 systems (dual chemical/light curing system) described
herein typically exhibit a flexural strength of about 25 to 60
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Additional aspects of the invention, together with the
advantages and novel features appurtenant thereto, will be set
forth in part in the description that follows, and in part will
become apparent to those skilled in the art upon examination
of the following, or may be learned from the practice of the
invention. The objects and advantages of the invention may be
realized and attained by means of the instrumentalities and
combinations particularly pointed out in the appended
claims.
BRIEF DESCRIPTION OF THE DRAWINGS

In another aspect, biomaterial compositions of the present
invention exhibit a flexural modulus greater than 1.5 GPa. For
example, the flexural modulus may be greater than about 1.5.
1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6,

beads or in another vehicular form.

55

MPa.

3.8, or 4.0 GPa (or have a value of some range therebetween).
For example, the P1 system (chemical curing system) typi
cally exhibits a flexural modulus of about 1.5 to 1.7 GPa, and
the P2 systems (dual chemical/light curing system) typically
exhibit a flexural strength of about 2.2 to 3.5 GPa.
In another aspect, the biomaterial compositions of the
present invention have a handling time between 5 and 15

4
minutes (e.g., 5, 6,7,8,9, 10, 11, 12, 13, 14, or 15 minutes (or
Some range therebetween), and preferably no longer than 20
minutes, when measuring the period of time required for the
compositions to harden or “set according to the Gillmore
Needle Test (ASTM C266-89). For example, the P1 system
(chemical curing system) and P2 systems (dual chemical/
light curing system) described herein typically exhibit a han
dling time of about 8 to 10 minutes.
Therefore, the present invention is directed to a biomaterial
composition which is an alternative to PMAA based bone
cements. For example, an ideal bone cement composition will
(1) provide a time-efficient means of reducing even Small
bone fragments to anatomically correct positions; (2) have the
same loading response as natural bone; (3) be biocompatible;
(4) possess the handling properties to allow for the Surgeon/
technician to Successfully place the material in the fracture
site in a controlled manner, and/or (5) not to integrate with the
bone, but be easily removed without significantly destroying
the tissue. It is anticipated that the biomaterial compositions
of the present invention will have one or more of these prop
erties, and preferably all of these properties.
The biomaterial compositions may be used as a bone and
dental cement, bone filler, bone anchor, and bone graft in
patients. For example, potential applications for the bioma
terial composition include, but are not limited to bone cement
(the adhesive or material used to join bone fragments together
or for placement and anchorage of prosthetic devices);
replacement of cartilage found in joints, e.g., knee meniscus,
temporomandibular joint, wrist, etc.; Vertebroplasty (the aug
mentation or mechanical support of a compromised verte
brae); bone filler (the material that fills cavities in bone either
permanently or temporarily as new bone fills in the defect):
bone scaffold; adjunct to metal cages for spinal fixation with
screws (the biomaterial may provide additional mechanical
Support); and Support of fractures to non-weight bearing
bones (e.g., the orbital bones of the face; and prosthetic spinal
disc nucleus). The biomaterial compositions of the present
invention may also be used for the delivery of heat sensitive
agents—including heat-sensitive antimicrobials and growth
factors—due to its low exotherm. For example, the biomate
rial compositions—combined with a heat-sensitive antimi
crobial or growth factor—maybe in the form of a spacer, or as

60

FIG. 1 shows cell growth responses of MLO-A5 cells for
chemically cured silorane resins (DCA, DCB, DCC) com
pared to the light cured silorane resin (PIH) after culturing
resins with cells for 24 and 48 hours. Panels a-d are from

65

Trypan blue data and panels e and fare from MTT data. The
asterisk (*) defines significantly different values (p<0.05)
from the light cure silorane (PIH).
FIG. 2 shows that the in vitro biocompatibility of the
chemical cure silorane resin (SilMixCC) is comparable to the
light cure silorane resin (SilMix LC) as demonstrated by the
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similar number of live and dead adherent and non-adherent
cells counted after 24 and 48 hours incubation with MLO-A5
cells.
FIG. 3 shows that the ultimate load to fracture of excised

mouse femora is similar when stabilized with either photo
initiated or dual chemical/light cured silorane resin.
FIG. 4 shows the chemical and dual chemical/light cured

5

silorane stress and modulus measurements. Panels a and b

illustrate the flexural strength and flexural modulus of the P1
and P2 systems compared to conventional PMMA systems.
Panels c and d illustrate the flextural strength and modulus of
two exemplary P1 systems. Panele illustrates the stress-strain
curve for an exemplary neat dual chemical/light cured system
comprising acetic acid, PIH, and camphorquinone.
FIG. 5 shows the exotherm temperature data for photoini
tiated and chemically initiated silorane resins. These results
show that the photoinitiated silorane has a much higher exo
therm (127°C.) than the chemically initiated (40° C.). The
chemically initiated silorane also has a longer curing time.
Note that the curing time presented for the chemical cure does
not take into account the additional one minute of mixing.
FIG. 6 is photographs of the silorane bone cement mimics.
The first sample (BCM 1/2) did not mix well and formed a
gritty clump of material. However, samples BCM 3/4 and
BCM5/6 were much smoother and polymerized with a glossy

10

15

As used herein, the term “chemical cure” refers to a cata

25

finish.

FIG. 7 is an exotherm profile of six exemplary biomaterial
compositions in accordance with the present invention.
BRIEF DESCRIPTION OF PREFERRED
EMBODIMENT

In the following description, certain details are set forth
Such as specific quantities, sizes, etc. So as to provide a thor
ough understanding of the present embodiments disclosed

30
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herein. However, it will be obvious to those skilled in the art

that the present disclosure may be practiced without such
specific details. In many cases, details concerning Such con
siderations and the like have been omitted inasmuch as Such

details are not necessary to obtain a complete understanding
of the present disclosure and are within the skills of persons of
ordinary skill in the relevant art.
The terms “comprises.” “comprising.” and variations
thereof do not have a limiting meaning where these terms
appear in the description and claims.
The recitation herein, of numerical ranges by endpoints is
intended to include all numbers subsumed within that range
(e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).

40

lytic system capable of catalyzing them polymerization of the
organosilicon monomers (preferably silorane monomers)
described herein independent of light. While the chemical
cure system may optionally include one or more components
of a light initiation system (e.g., PIH), the chemical cure
system is capable of polymerizing the organosilicon mono
mers (preferably silorane monomers) in the dark.
As used herein, the term "dual' curing system means and
refers to a system that cures at least partially by light-cure
(electromagnetic radiation) and at least partially by a chemi
cal cure. As discussed more fully below, the dual chemical/
light curing system may contain on or more accelerators,
photosensitizers, and/or reaction promoters. Light (typically
ultraviolet, visible, or infrared) is needed in order for the
complete curing to occur.
Molecular terms, when used in this application, have their
common meaning unless otherwise specified. It should be
noted that the alphabetical letters used in the formulas of the
present invention should be interpreted as the functional
groups, moieties, or substituents as defined herein. Unless
otherwise defined, the symbols will have their ordinary and
customary meaning to those skilled in the art.
The term “alkyl embraces a branched or unbranched satu
rated hydrocarbon group of 1 to 12 carbon atoms, such as
methyl, ethyl, n-propyl, isopropyl. n-butyl, isobutyl, t-butyl,
octyl, decyl, tetradecyl, as well as cyclic alkyl groups and the
like.

45

As used herein, “a” or 'an' means “at least one' or “one or

more' unless otherwise indicated. In addition, the singular
forms “a,” “an and “the include plural referents unless the
content clearly dictates otherwise. Thus, for example, refer
ence to a composition containing "a compound includes a
mixture of two or more compounds. As used in this specifi
cation and the appended claims, the term 'or' is generally
employed in its sense including “and/or unless the content
clearly dictates otherwise.
Unless otherwise indicated, all numbers expressing quan
tities of compounds, measurement of properties, and claims
are to be understood as being modified in all instances by the
term “about. Accordingly, unless indicated to the contrary,
the numerical parameters set forth in the foregoing specifica
tion and attached claims are approximations that can vary
depending upon the desired properties sought to be obtained
by those skilled in the art utilizing the teachings of the present
invention. At the very least, and not as an attempt to limit the
application of the doctrine of equivalents to the scope of the

6
claims, each numerical parameter should at least be construed
in light of the number of reported significant digits and by
applying ordinary rounding techniques. Notwithstanding that
the numerical ranges and parameters setting forth the broad
Scope of the invention are approximations, the numerical
values set forth in the specific examples are reported as pre
cisely as possible. Any numerical value, however, inherently
contains certain errors necessarily resulting from the standard
deviations found in their respective testing measurements.
As used herein, the term "patient' encompasses humans
and domestic animals including pets and farm animals, exotic
animals as found in Zoos and similar preserves, and research
animals as used in public and private research institutions,
e.g., monkeys, chips, cats, dogs, horses, pigs, sheep, cows,
monkeys, rats, mice, guinea pigs, and rabbits.

50

The term “alkoxy” embraces an alkyl group attached to an
oxygen. Examples include, without limitation, methoxy,
ethoxy, tert-butoxy, and cyclohexyloxy. Most preferred are
“lower alkoxy' groups having one to six carbon atoms.
Examples of Such groups include methoxy, ethoxy, propoxy,
butoxy, isopropoxy, and tert-butoxy groups.
The term “alkenyl embraces unsaturated aliphatic groups
analogous in length and possible Substitution to the alkyls
described above, but that contain at least one double bond.

55

60

65

Examples include propenyl, 1-butenyl, 2-butenyl, 3-butenyl,
2-methylpropenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl,
4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-me
thyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl,
3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-bute
nyl, 3-methyl-3-butenyl, and the like.
The term “alkenoxy” embraces an alkenyl group attached
to an oxygen. Examples include allyloxy, 1-propenyloxy,
isopropenyloxy, methallyloxy, 2-butenyloxy, 1-butenyloxy,
isobutyloxy, pentenyloxy, hexenyloxy, octenyloxy, or dece
nyloxy.
The term “alkenoxyalkyl embraces an alkenoxy-substi
tuted alkyl moiety. Examples include allyloxymethyl, ally
loxyethyl, allyloxypropyl, and methallyoxymethyl.

US 9, 186,302 B2
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The term “aryl” embraces a carbocyclic aromatic system
containing one, two, or three rings wherein Such rings may be
attached together in a pendant manner or may be fused. The
term “fused’ means that a second ring is present (i.e., attached
or formed) by having two adjacent atoms in common (i.e.,
shared) with the first ring. The term “fused' is equivalent to
the term “condensed.” The term “aryl” embraces aromatic
groups such as phenyl, naphthyl, tetrahydronaphthyl, indane,
and biphenyl.
The term “arylalkyl or “aralkyl embrace aryl-substituted
alkyl moieties. Preferable aralkyl groups are “lower aralkyl
groups having aryl groups attached to alkyl groups having
one to six carbon atoms. Examples of Such groups include
benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and
diphenylethyl. The terms benzyl and phenylmethyl are inter
changeable.
The term “aryloxy” embraces aryl groups, as defined
above, attached to an oxygen atom, such as phenoxy.
The term “aralkoxy' or “arylalkoxy” embrace aralkyl
groups attached through an oxygen atom to other groups.
“Lower aralkoxy' groups are those phenyl groups attached to
lower alkoxy group as described herein. Examples of Such
groups include benzyloxy, 1-phenylethoxy, 3-trifluo
romethoxybenzyloxy, 4-propylbenzyloxy, and 2-phe
nylethoxy.
The term silyl refers to the group —SiHi. The silyl group
may be optionally Substituted with one or more alkyl, aryl,
arylalkyl, alkoxy, aryloxy, arylalkoxy groups, or combina
tions thereof. Thus, for example, the term “alkylsilyl
embraces a silyl group Substituted with one or more alkyl
groups, such as methylsilyl dimethylsilyl, trimethylsilyl eth
ylsilyl, diethysilyl, triethylsilyl, and the like. The term “aryl
silyl similarly refers to a silyl group substituted with one or
more aryl groups, such as phenylsilyl. The term “arylalkylsi
lyl refers to a silyl group substituted with one or more ary
lalkyl groups. The term alkoxysilyl refers to a silyl group
substituted with one or more alkoxy groups. The term “ary
loxysilyl embraces silyl groups substituted with one or more
aryloxy groups. The term “arylalkoxysilyl embraces silyl
groups substituted with one or more arylalkoxy groups.
The term “siloxy' embraces oxy-containing groups Substi
tuted with a silyl group. The siloxy group may be optionally
Substituted with one or more alkyl, aryl, arylalkyl, alkoxy,
aryloxy, arylalkoxy groups, or combinations thereof. Thus,
for example, the term “alkylsiloxy' embraces a siloxy group
substituted with one or more alkyl groups. The term “arylsi
loxy” embraces a siloxy group Substituted with one or more
aryl groups. The term “arylalkylsiloxy” embraces a siloxy
group Substituted with one or more arylalkyl groups. The
term “alkoxysiloxy” embraces a siloxy group substituted
with one or more alkoxy groups. The term “aryloxysiloxy”
embraces a siloxy group Substituted with one or more aryloxy
groups. The term “arylalkoxysiloxy” embraces a siloxy group
Substituted with one or more arylalkoxy groups.
The term “silylalkyl embraces silyl-substituted alkyl moi
eties. The silylalkyl groups may be optionally substituted
with one or more alkyl, aryl, arylalkyl, alkoxy, aryloxy, ary
lalkoxy groups, or combinations thereof. Thus, for example,
the term “alkylsilylalkyl embraces methylsilylpropyl, dim
ethylsilylpropyl, thmethylsilylpropyl, and the like. The term
“arylsilylalkyl embraces aryl-substituted silylalkyl groups.
The term “arylalkylsilylalkyl embraces arylalkyl substituted
silylalkyl groups. The term “alkoxysilylalkyl embraces
alkoxy substituted silylalkyl groups. The term “aryloxysily
lalkyl embraces aryloxy substituted silylalkyl groups. The
term “arylalkoxysilylalkyl embraces arylalkoxy substituted
silylalkyl groups.
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8
The term “siloxyalkyl embraces siloxy-substituted alkyl
groups. The siloxyalkyl groups may be optionally Substituted
with one or more alkyl, aryl, arylalkyl, alkoxy, aryloxy, ary
lalkoxy groups, or combinations thereof. Thus, the term
“alkylsiloxyalkyl embraces alkyl substituted siloxyalkyl
groups. The term “arylsiloxyalkyl embraces aryl substituted
siloxyalkyl groups. The term “arylalkylsiloxyalkyl
embraces arylalkyl Substituted siloxyalkyl groups. The term
“alkoxysiloxyalkyl embraces alkoxy substituted siloxyalkyl
groups. The term “aryloxysiloxyalkyl embraces aryloxy
substituted siloxyalkyl groups. The term “arylalkoxysiloxy
alkyl embraces arylalkoxy Substituted siloxyalkyl groups.
The term “silylalkoxy” embraces silyl-substituted alkoxy
groups. The silylalkoxy group may be optionally Substituted
with one or more alkyl, aryl, arylalkyl, alkoxy, aryloxy, ary
lalkoxy groups, or combinations thereof. Thus, for example,
the term “alkylsilylalkoxy” embraces alkyl substituted sily
lalkoxy groups. The term “arylsilylalkoxy” embraces aryl
substituted silylalkoxy groups. The term “arylalkylsilyla
lkoxy' embraces arylalkyl Substituted silylalkoxy groups.
The term “alkoxysilylalkoxy” embraces alkoxy substituted
silylalkoxy groups. The term “aryloxysilylalkoxy” embraces
aryloxy substituted silylalkoxy groups. The term “arylalky
loxysilylalkoxy” embraces arylalkyloxy substituted silyla
lkoxy groups.
The term “siloxyalkoxy” embraces siloxy-substituted
alkoxy groups. The siloxyalkoxy group may be optionally
Substituted with one or more alkyl, aryl, arylalkyl, alkoxy,
aryloxy, arylalkoxy groups, or combinations thereof. Thus,
for example, the term “alkylsiloxyalkoxy” embraces alkyl
substituted siloxyalkoxy groups. The term “arylsiloxy
alkoxy” embraces aryl substituted siloxyalkoxy groups. The
term “arylalkylsiloxyalkoxy” embraces arylalkyl substituted
siloxyalkoxy groups. The term “alkoxysiloxyalkoxy.'
embraces alkoxy Substituted siloxyalkoxy groups. The term
“aryloxysiloxyalkoxy” embraces aryloxy substituted siloxy
alkoxy groups. The term “arylalkoxysiloxyalkoxy' embraces
arylalkyloxy Substituted siloxyalkoxy groups.
The biomaterial composition of the present invention com
prises an organosilicon monomer (such as a silorane) and a
chemical curing system or dual chemical/light curing system
for polymerizing the monomer. The compositions may also
contain TOSUs and/or fillers. The compositions may also
include one or more accelerators, such as photoacids. Photo
sensitizers, and/or reaction promoters may also included in
the biomaterial composition having the dual chemical/light
curing systems. In addition, one or more pre-polymerized
organosilicon monomers may also be included in the bioma
terial composition. The pre-polymerized organosilicon
monomers essentially function as a filler in the overall bio
material composition.
In an exemplary aspect, the biomaterial composition com
prises about 30 to 60 wt % (e.g., about 30, 35, 40, 45, 50, 55,
or 60 wt % most preferably about 40 to 55 wt %) organo
silicon monomer (e.g., silorane co-monomer, Such as Sil
Mix); about 0 to 50 wt % (e.g., about 1, 2, 3, 4, 5, 10, 15, 20,
25, 30,35, 40, 45, or 50 wt % most preferably about 25 to 50
wt %) pre-polymerized organosilicon monomer (e.g., pre
polymerized silorane filler, such as SilMix); about 0 to 25 wt
% (e.g., about 5, 10, 15, 20, or 25 wt % most preferably
about 10 to 20 wt %) other filler (e.g., glass, such as an
unmodified glass filler); and about 0.05 to 5 wt % (e.g., about
0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8,
0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6,
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2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 wt %)
of the chemical cure or dual chemical/light curing system. For
example, the chemical cure system may comprise about 0.05
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to 1.0 wt % (most preferably about 0.05 to 0.2 wt %) p-(oc
tyloxyphenyl)phenyliodonium hexafluoroantimonate and
about 0.05 to 1.0 wt % (most preferably about 0.09 to 0.2 wt
%) Lamoreaux's catalyst.
As another example, the biomaterial composition com
prises about 30 to 60 wt % (e.g., about 30, 35, 40, 45, 50, 55,
or 60 wt % most preferably about 35 to 50 wt %) organo
silicon monomer (e.g., silorane co-monomer, Such as SilMix)
and about 0 to 80 wt % (e.g., about 5, 10, 15, 20, 25, 30, 35,
40, 45, 50, 55, 60, 65, 70, 75, or 80 wt % most preferably
about 45 to 65 wt %) filler (e.g., DY5 filler modified with
ECHE, 3TOSU, or 1TOSU); and about 0.05 to 5 wt % (e.g.,
about 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,0.3, 0.4,0.5,0.6,
0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2,
2.4, 2.6.2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, or 5.0

wt %) of the chemical cure or dual chemical/light curing
system. For example, the dual chemical/light curing system
may comprise about 0.05 to 1.0 wt % (preferably about 0.3 to
0.8 wt %) Lamoreaux's catalyst and a photoinitiation system
comprising about 1 to 5 wt % of an accelerator (e.g., about 3
wt % PIH), about 0.05 to 2 wt % photosensitizer (e.g., about
1 wt % camphorquinone), and 0.05 to 0.5 wt % electron donor
(e.g., about 0.15 wt % EDMAB).
As another example, the biomaterial composition com
prises about 20 to 98 wt % (e.g., about 30, 35, 40, 45, 50, 55,

10

15

ethyl-dimethyl-silane (DiMe-Sil:

MF, C.H.O.S: 97% purity), and 1,3,5,7-tetrakis(ethy

25
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about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,

or 80 wt % most preferably about 45 to 65 wt %) filler (e.g.,
DY5 filler modified with ECHE, 3TOSU, or 1TOSU); and
about 0.05 to 5 wt % (e.g., about 0.05, 0.06, 0.07, 0.08, 0.09,

35

0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5,
1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8,

4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 wt %) of the chemical cure or dual
chemical/light curing system. For example, the dual chemi
cal/light curing system may comprise a mixture and acid
(preferably a Bronsted acid), photoacid, and a photosensi
tizer. The ratio of the Bronsted acid to the photoacid is pref
erably between about 3:1 to 1:3 by weight (e.g., about 3:1,
2:1, 1:1, 1:2, and 1:3). The ratio of the Bronstead acid to the
photosensitizer is preferably about 10:1 to 1:1 by weight (e.g.,
about 10:1, 8:1, 5:1, 3:1, and 1:1). In an exemplary aspect, the
biomaterial composition may comprise a dual chemical/light
cure system comprised of acetic acid, PIH, and cam
phorquinone at a ratio of about 3:3:1 percent by weight, e.g.,

40

45

50

about 3 wt % acetic acid, 3 wt % PIH, and 1 wt % cam

phorquinone (for a neat biomaterial composition containing
no filler) and 1.5 wt % acetic acid, 1.5% PIH, and 0.5%
camphorquinone (for a 50% filled biomaterial composition).
Each of the components of the composition of the present

55

invention will now be described in further detail.

Organosilicon Monomers
Various organosilicon monomers useful in the biomaterial
compositions of the present invention are set forth in Chap
pelow, U.S. Published Patent Application No. 2007/0072954;

60

Weinmann et al., U.S. Pat. No. 6,908,953: Weinmann et al.,

U.S. Pat. No. 6.245,828 entitled “Polymerizable Composi
tions Based on Epoxides’ and Bissinger et al., U.S. Pat. No.
6,624.236 entitled “Cyclosiloxane-Based Cross-Linkable

RY 349660-80-6:

MF, as Si; 95% purity), 1,4-bis(2,3-epoxypropylox
ypropyl-dimethylsilyl)benzene (Phen-Glyc: RN 18715-54-3:

60, 65, 60, 65,70, 75,80, 85,90,91, 92,93, 94, 95, 96, 97,98

wt % most preferably about 90 to 98 wt % for the “neat”
biomaterial composition) organosilicon monomer (e.g., silo
rane co-monomer, such as SilMix); about 0 to 80 wt % (e.g.,

10
Monomers, Production Thereof in Polymerizable Materials;”
Weinmann et al., Siloranes in dental composites, Dent. Mater.
21(1) 68-74 (2005); Eicket al., Properties of silorane-based
dental resins and composites containing a stress-reducing
monomer, Dent. Mater. 23(8) 1011-1017 (2007); all of which
are incorporated by reference. Most preferred organosilicon
monomers are "siloranes, which generally refer to silicon
containing monomers having an oxirane (epoxide) and pref
erably a siloxane (e.g., Si-O bond or Si-O-Si-O).
A variety of organosilicon compounds with oxirane func
tionality were first synthesized and polymerized by Sato et
al., JP Patent No. 51033541 (Sep. 20, 1976). Similar com
pounds were studied by Crivello and others. See Crivello et
al., European Patent No. 574264 (1993); and Crivello et al.,
European Patent No. 412430 (1991), which are incorporated
by reference. Most preferred are multifunctional
cycloaliphatic siloxane-based oxiranes. Exemplary organo
silicon monomers useful for forming the dental matrix resins
of the present invention include di-3,4-epoxy cyclohexylm
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cyclohexane epoxy)-1,3,5,7-tetramethyl cyclotetrasiloxane
(CYGEP: RN 121225-98-7, MF, C.H.O.S., 98% purity),
all available from 3M-ESPE (St. Paul, Minn.). Exemplary
siloranes are set forth in Weinmannet al., Volume shrinkage of
a new filling material based on siloranes, J. Dent. Res. 80(SI)
780 Abstr. No. 2027 (2001); Weinmann et al., Comparative
testing of volumetric shrinkage and sealing of silorane and
methacrylate filling materials, J. Dent. Res. 81 (SI-A) 417
Abstr. No. 3382 (2002); Dede et al., Comparison of two ways
to determine polymerization shrinkage of composites, J.
Dent. Res. 83 (SI-A) Abstr. No. 0057 (2004); Guggenbergeret
al., Exploring beyond methacrylates, Am J Dent. 1382D-84D
(November 2000); Schwekl, The induction of gene mutations
and micronuclei by Oxiranes and siloranes in mammalian
cells in vitro, J. Dent. Res. 83(1) 17-21 (January 2004); Eick
et al., Stability of silorane dental monomers in aqueous sys
tems, J. Dent. 34 (6) 405-410 (2006), Watts, Shrinkage-Stress
Kinetics of Silorane versus Dimethacrylate Resin-Compos
ites, 12 Baltimore Convention Center 322-323 (Abstract)
(March 2005); and Klettke et al., U.S. Pat. No. 6,779.656,
which are all incorporated by reference.
Combinations of organosilicon monomers may also be
utilized in the biomaterial compositions of the present inven
tion. For example, SilMix is comprised of a 1:1 w/w (2:1
mol/mol) ratio of methylbis 2-(7-Oxabicyclo[4.1.0 hept-3yl)ethylphenylsilane I (“PHEPSI) and 2,4,6,8-tetramethyl
2,4,6,8-tetrakis-2-(7-Oxabicyclo4.1.0 hept-3-yl)ethyl-1,3,
5,7-tetraoxa-2,4,6,8-tetrasilacyclooxtane II (“CYGEP')
produced by 3M-ESPE (St. Paul, Minn.). The structures Sil
Mix compounds are shown below:
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-3-

50° C.

PtCl2 Complex

In one aspect, Lamoreaux's catalyst may be prepared by
heating the reaction mixture to 70° C. at 25 mm Hg for 40
hours as discussed in the patent references. In another aspect,
Lamoreaux's catalyst may be prepared by heating the reac
tion mixture (chloroplatinic acid hexahydrate and octanol
(98%) combined in a 1:7 mole ratio) to 50 to 55° C. under
vacuum at 0.01 mm Hg for about 40 to 42 hours. After that
time, the solution was filtered and washed with hexanes. The

15

The organosilicon monomers used in the biomaterial com
positions of the present invention are preferably prepared at
purities greater than 90%, and most preferably greater than

95% as determined by H NMR spectroscopy.
The organosilicon monomers preferably comprises about
20 to 98 wt % (e.g., about 20, 30, 40, 50, 60, 70, or 80%), and
in some aspects, more preferably about 40 to 60 wt % of the
composition. Furthermore, as discussed below, the mono
mers may be pre-polymerized prior to addition to the com
position so that the biomaterial composition comprises both
unpolymerized monomers and pre-polymerized polymer
prior to polymerization. Typically, the ratio of unpolymerized
monomers (e.g., SilMix co-monomer) to polymer (e.g., pre
polymerized Sil Mix) is about 1:5 to 5:1 (e.g., about 1:5, 1:4,
1:3, 1:2, 1:1, 2:1, 3:1, 4:1, or 5:1, or some range therebe
tween). For biomaterial compositions containing pre-poly
merized organosilicon monomers, the polymer is preferably
crushed or ground to a particle size (typically irregular in
shape) of about 0.5 to 15um (e.g., 0.5, 1, 3, 5, 7, 9, 11, 13, or
15um, or some range therebetween) with a number average
size of about 2 Lum. The pre-polymerized organosilicon
monomer essentially functions as a filler in the overall com
position.
Cure/Initiation Systems
The biomaterial compositions of the present invention also
include a chemical curefinitiation system or a dual chemical/
light curing system.
1. Chemical Cure/Initiation System
In one aspect, the chemical curing system comprises a
hydrosilation catalyst which may be used to effect the addi
tion of the ethylenically unsaturated epoxide or epoxide/or
ganic mixture. Preferred catalysts are those taught by Lam

25

those described in Akizumi et al., U.S. Published Patent
30

35

Application No. 2011/0172323, which is incorporated herein
by reference. Most preferred accelerators are aryl-based
iodonium salts, in particular a phenyl iodonium salt.
Examples of Such accelerators include, but are not limited to,
(4-n-octyloxyphenyl)phenyliodonium hexafluoroantimonate
(“PIH'), which may be obtained from GE Silicones under
number 479-2092C: 4-(2-hydroxytetradecyloxyphenyl)
phenyliodonium hexafluoroantimonate (CD 1012), which
may be obtained from Sartomer under the trade name SarCat
CD-1012 or from Gelest under the trade name OMANO72:

40

4-1-methylethyl)phenyl(4-methylphenyl)iodonium tetrak
is(pentafluorophenyl)borate(1-) (RHO2074), which may be
obtained from Rhodia, Inc., under the trade name Rhodorsil
Photoinitiator 2074; and combinations thereof. See also,

45

50

oreaux in U.S. Pat. Nos. 3,917,432: 3, 197433; and 3,220,

972, which are all hereby incorporated by reference. The
platinum catalyst disclosed in the patents to Lamoreaux is a
complex formed from chloroplatinic acid with up to about 2
moles per gram of platinum of a member selected from the
class consisting of alcohols, ethers, aldehydes, and mixtures
of the above. This catalyst will sometimes be referred to
herein as the “Lamoreaux catalyst.”
In a preferred aspect, the chemical curing system com
prises a Lamoreaux's catalyst which involves either PtCl
with aldehyde and ether linkages derived from octanol. This
catalyst was synthesized from chloroplatinic acid HPtCle.
using an adapted procedure by Lamoreaux, U.S. Pat. No.
3.220,972, which is incorporated by reference.

filtrate was placed under vacuum (0.01 mm Hg) at room
temperature for about 8 to 12 hours. The resulting liquid was
stored under inert atmosphere in the refrigerator.
Further, other organometallic catalysts, such as those con
taining ruthenium, rhodium, iridium, palladium, platinum,
iron, osmium, cobalt, molybdenum, tungsten, nickel, copper,
gold, silver, Zirconium, and titanium (most preferably Pt and/
or Rh) are also possibilities for chemical curing. For example,
for platinum-based catalysts, Wilkinson's catalyst, Speier's
catalyst, and Karstedt's catalyst may also be employed, while
Grubb’s catalyst may be a suitable ruthenium-based catalyst.
The chemical curing system may optionally contain an
accelerator. A preferable accelerator is a photoacid, such as

similar compounds discussed in Yamtao et al., WO 2002/
046507, which is incorporated by reference. Although such
accelerators have been traditionally used in light initiated
polymerization systems, they also may be used in the chemi
cal-initiated polymerization composition of the present
invention. The mechanism by which the photoacid (e.g., PIH)
reacts with the organometallic catalyst (e.g., Lamoreaux's
catalyst) to permit polymerization in the dark when using this
exemplary chemical curing system of the present invention is
not known.
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It will be appreciated that chemical curing system does not
require a photosensitizer or reaction promoter (although Such
compounds could optionally be included in the composition).
The chemical curing system preferably comprises about
0.05 to 2 wt % (e.g., 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2,0.3,
0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7,

1.8, 1.9, or 2.0 wt %) of the biomaterial composition. For
example, the chemical cure system may comprise about 0.1 to
1.0 wt % of the photoacid (e.g., about 0.05 to 0.4 wt %,
preferably about 0.05 to 0.2 wt %, of p-(octyloxyphenyl)
phenyliodonium hexafluoroantimonate) and about 0.05 to 1.0
wt % organometallic catalyst (e.g., about 0.1 to 0.4 wt %,
preferably about 0.09 to 0.2 wt % Lamoreaux's catalyst).
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2. Dual Chemical/Light Cure/Initiation System
obtained from Aldrich under the number 12, 489-2 with a
In another aspect, the biomaterial compositions of the 97% purity: 2-chlorothioxanthen-9-one (“CTXO), which
present invention comprise a dual chemical/light cure system. may be obtained from Aldrich C7-240-4; and combinations
One exemplary dual chemical/light cure system comprises a thereof.
mixture of a chemical curing agent (Such as an acid or one of 5 Reaction Promoter (Electron Donor)
Another preferred component of the dual chemical/light
the organometallic catalysts referenced herein), along with an
accelerator (see examples above), photosensitizer, and/or curing system is one or more electron donor compounds,
reaction promoter.
which functions as a reaction promoter. A class of donor
Chemical Curing Agent (e.g. Acetic Acid Containing Sys compounds that may be useful in the inventive systems may
10 be selected from some of the electron donors described in
tems)
The dual chemical/light cure system may include an acid. Chappelow et al., U.S. Pat. No. 6,653,486 and Palazzotto et
In the present invention, Various Lewis aids, Bronsted acids, al., U.S. Pat. No. 5,545,676, which are both incorporated by
and Super acids were investigated. The acids investigated reference. Preferred electron donor compounds include sub
included hydrochloric acid, acetic acid (AA'), phosphoric stituted amines, e.g., ethyl dimethylaminobenzoate. The pre
acid, Sulfuric acid, hydrobromic acid, hydroiodic acid, 15 ferred electron donor that may be used in the composition of
trichloroacetic acid, trifluoroacetic acid, p-toluenesulfonic the present invention include, but are not limited to, ethyl
acid, borontrifluoride, aluminium chloride, tin (IV) chloride, p-dimethylaminobenzoate (“EDMAB), which may be
titanium chloride, pentafluoroproprionic acid, triflic acid, obtained from Acros under number 11840-1000 at 99.9%
hexafluorophosphoric acid (“HFPA), ethyl triflate, potas purity; 4,4'-bis(diethylamino)benzophenone (“BDEAB),
sium t-butoxide, and mixtures thereof (e.g., AA/HFPA, phos which also may be obtained from Acros under number 17081
phoric acid/TiCl, phosphoric acid/triflic acid, phosphoric 0250s at 99% purity; and combinations thereof.
The dual chemical/light curing system preferably com
acid/p-toluene Sulfonic acid, and phosphoric acid/trifluoro
prises about 0.05 to 5 wt % (e.g., 0.05, 0.06, 0.07, 0.08, 0.9,
acetic acid).
The preferred acid investigated is acetic acid. Thus, in one 0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4,
aspect, the preferred acid is a weak/mild monoprotic acid 25 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6,
which is nontoxic and biocompatible. The acid preferably has 3.8, 4.0, 4.2, 4.4, 4.6, 4.8, or 5.0 wt %) of the biomedical
a pKa between about 3 and 6 (e.g., 3, 4, 5, or 6), exhibits low composition.
Volatility, and is soluble in the organic monomers being poly Exemplary Dual Chemical/Light Curing Systems
merized.
In exemplary embodiments, the dual chemical/light curing
Photosensitizer
30 system may comprise 0.05 to 0.2 wt % (preferably about 0.3
The dual curing system also preferably includes one or to 0.8 wt %) Lamoreaux's catalyst and a photoinitiation sys
more photosensitizers. Exemplary photosensitizers are dis tem comprising about 1 to 5 wt % of an accelerator (e.g.,
closed in Chappelow et al., U.S. Pat. No. 6,653,486, which is about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5 or 5 wt %, preferably about
incorporated by reference. Suitable sensitizers include com 3 wt % PIH), about 0.05 to 2 wt % photosensitizer (e.g., about
pounds in the following categories: ketones, coumarin dyes 35 0.05, 1, 1.5, 2 wt %, preferably about 1 wt % cam
(e.g., ketocoumarins), Xanthene dyes, acridine dyes, thiazole phorquinone), and 0.05 to 0.5 wt % electron donor (e.g., 0.05,
dyes, thiazine dyes, oxazine dyes, azine dyes, aminoketone 0.1, 0.15, 0.2,0.25, 0.3, 0.35, 0.4,0.45, 0.5 wt %, preferably
dyes, porphyrins, aromatic polycyclic hydrocarbons, p-sub about 0.15 wt % EDMAB).
stituted aminostyryl ketone compounds, aminotriaryl meth
In another exemplary aspect, the dual chemical cure sys
anes, merocyanines, squarylium dyes and pyridinium dyes. 40 tem comprises an acid (e.g., acetic acid), a photosensitizer
Ketones (e.g., monoketones or alpha-diketones), ketocou (e.g., camphorquione), and a photoacid (e.g., PIH). The ratio
marins, aminoarylketones, and p-substituted aminostyryl of the Bronsted acid to the photoacid is preferably between
ketone compounds are preferred sensitizers. For example, about 3:1 to 1:3 by weight (e.g., about 3:1, 2:1, 1:1, 1:2, and
Such photosensitizers include, but are not limited to as 2.2-,
1:3). The ratio of the Bronstead acid to the photosensitizer is
4.4- or 2,4-dihydroxybenzophenone, di-2-pyridyl ketone, 45 preferably about 10:1 to 1:1 by weight (e.g., about 10:1, 8:1,
di-2-furanyl ketone, di-2-thiophenyl ketone, benzoin, fluo 5:1, 3:1, and 1:1). For example, the composition may com
prise a dual chemical/light cure system comprised of acetic
renone, chalcone, Michler's ketone, 2-fluoro-9-fluorenone,
2-chlorothioxanthone, acetophenone, benzophenone, 1- or acid, PIH and camphorquinone at a ratio of about 3:3:1 per
2-acetonaphthone, 9-acetylanthracene, 2-, 3- or cent by weight. For example, the composition may comprise
9-acetylphenanthrene, 4-acetylbiphenyl, propiophenone, 50 about 1.5 wt % acetic acid, 1.5% PIH, and 0.5% cam
n-butyrophenone, Valerophenone, 2-, 3- or 4-acetylpyridine, phorquinone (for a 50% filled composition). The percentage
3-acetylcoumarin and the like. Suitable diketones include by weight is preferably 3:3:1 of AAPIH:CQ.
aralkyldiketones such as anthraquinone, phenanthrene Fillers
quinone, o-, m-, and p-diacetylbenzene, 1.3-, 1.4-, 1.5-, 1.6-,
The biomaterial compositions may further comprise one or
17- and 1,8-diacetylnaphthalene, 1.5-, 1.8- and 9,10-diacety 55 more fillers. These fillers can possess a variety of morpholo
lanthracene, and the like. Suitable alpha-diketones include gies such as, but not limited to, needles, rods, particulate,
2,3-butanedione, 2.3-pentanedione, 2.3-hexanedione, 3,4- flakes, plates, cylinders, long fibers, whiskers, or spherical
hexanedione, 2.3-heptanedione, 3,4-heptanedione, 2.3-oc particles. In some embodiments that may be preferred, the
tanedione, 4.5-octanedione, benzyl, 2,2'-3,3'- and 4,4'-dihy filler is comprised of particles with an average particle size
droxylbenzyl, furyl, di-3,3'-indolylethanedione, 2.3- 60 which is in the Sub-micron or nanoparticle range, e.g., less
bomanedione
(camphorquinone),
biacetyl,
1.2than about 1.0 um. Exemplary particle sizes are about 10, 20,
cyclohexanedione, 1.2-naphthaquinone, acenaphthaquinone, 30, 40, 50, 60, 70, 80,90, 100, 150, 200, 250, 300, 350, 400,
and the like.
450, 500, 600, 700, 900, or 1000 nm or some range therebe
A preferred photosensitizer is an alpha-dicarbonyl com tWeen.
pound. Examples of specific photosensitizers that may be 65 Given the appropriate interactions and dispersion qualities,
used in the composition of the present invention include, but particle size may be a critical factor in that nanoparticles can
are not limited to, (+/-) camphorquinone, which may be produce dramatic changes in the mechanical properties of the
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composition as compared to micrometer sized fillers at com
parable Volume loading to analogous nanoparticle compos
ites. For example, improvements in tensile strength and
modulus offive- and seven-fold may be obtained for compos
ites containing only 1.5% nanoclay particles. Similar low
loadings with resulting increased properties have been
reported elsewhere. Surprisingly, higher concentrations of
nanoparticles made little further improvement. Improved
strength and wear properties at low filler Volume loading are
anticipated if the particles are not subject to being ablated
from the matrix, i.e., are prevented from discreet particle
ablation by covalent bonding of the particles into the polymer

10

matrix.

The filler may be comprised of an inorganic or organic
material, which may be bioactive. In certain embodiments,
the filler is comprised of an inorganic material.
Suitable fillers may be particulate or fibrous fillers with
sizes in the nanoparticle to microparticle range. Fillers should
be capable of being covalently bonded to the resin matrix
itself or to a coupling agent that provides bonding to the filler
and then the Surrounding resin matrix. Examples of Suitable
filling materials include but are not limited to amorphous
silica; spherical silica; colloidal silica, clays; barium glasses;
quartz; ceramic fillers; silicate glass; hydroxyapatite; calcium

15
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Composition of the macro and micro fillers will not be iden
tical or perhaps even similar. Nanoparticles will be typically
high purity, high strength whiskers/rod/fibers/platelets, while
the macrofiller will typically be a silica-based ally glass with
additive elements for strength and hardness.
In another aspect, examples of suitable fillers include, but
are not limited to, barium glass, barium-boroaluminosilicate
glass, sodium borosilicate, silica, 45S5 glass, bioactive glass,
ceramics, glass-ceramics, bioactive synthetic combeite glass
ceramic, e-glass, S-glass, iron phosphate, or combinations
thereof. The most preferred fillers are yttria alumino silicate
(e.g., DY5; see table below) and barium boroaluminosilicate
(e.g., M12, see table below), and alumina or Zirconia nano
rods.
Preferred glass fillers can be made by either melting
batches (M-series and alkali-containing DY-series) or by sin
tering batches and spheroidization of the sinter (alkali-free
DY-series). The sinter/spheroidization process was used for
batches that melted above 1550° C. The nominal chemical

composition and n of the M-series glasses are given in Table
1 below. The nominal chemical composition and n of the
DY-series glasses are listed in Table 2 below. The n of the
glasses varied from 1.48 to 1.56 depending on composition, a
range of values which is needed for reinforcing blue-light
(440 nm)-curable composites.
TABLE 1.

Nominal Weight Percent Composition and Refractive Index of M-Series
Filler Code
M1
M2
M3
M4
M5
M6
M7
M8
M9
M10

Li2O Na2O K2O MgO BaO CaO YO. ZrO2 YbO,
3
3
3
3
O
O
O
O
O
3

O
O
O
O
1
1
10
6
5
O

O
O
O
O
O
O
O
8
6
O

2
2
2
2
8
2
1
O
O
2

9
9
9
9
O
O
O
2
O
9

O
O
O
O
O
22
6
6
O
O

3
3
O
3
O
O
O
O
O
3

O
O
O
O
9
5
22
5
5
O

ZnO TiO2 B2O.

O
O
3
O
O
O
O
O
O
O

O
O
O
O
O
O
O
5
7
O

O
O
O
O
O
O
O
O
4
O

Al2O.

S8
29
29
S8
O
7
3
O
8
S8

SiO2 AIF

14
14
14
O
21
11
4
2
4
14

8
37
37
22
61
S2
S4
66
61
8

3
3
3
3
0
O
O
O
0
3

in
1.53
152
152
1.53
1.52
1.56
1.56
1.52
1.52
1.52
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carbonate; fluoroaluminosilicate; barium sulfate; quartz;
barium silicate; strontium silicate; barium borosilicate;

TABLE 2

barium boroaluminosilicate;
strontium borosilicate; strontium boroaluminosilicate; bioactive glass; dental glass iono

Nominal
Weight Percent Composition and
Refractive Index of DY-Series Glasses

mer filler; silicate or phosphate based glass fibers; lithium * Filler Code

Y2O,

Yb2O3.

Al2O3

silicate; ammoniated calcium phosphate; deammoniated cal-

DYb1

O

23

21

56

O
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cium phosphate; calcium tungstate; alumina; Zirconia; tin
oxide; Zinc oxide; calcium oxide; magnesium oxide, postassium oxide, barium oxide yttrium oxide, bismuth compounds
Such as bismuth oxychloride and bismuth oxide; polymer
powders such as polymethyl methacrylate, polystyrene, and

DY2
DY3
DY4
DY5*
DY6
DY7

1
3
15
15
15
14

O
O
OO
O
O

9
9
215
15
14

90
88
64
8O
70
67

O
O
OO
O
5

148
148
1.56
1.52
1.53
1.52

O

152

50

SiO2 Na2O

in

polyvinyl chloride; titanium dioxide; bound and nano struc-

R

t

g

t

5.

tured silica fillers as set forth in U.S. Pat. No. 6,417,246,

DY1O

O

23

21

56

embrittled glass fibers or particles as set forth in U.S. Pat.

cký

Nos. 6,013,694 and 6,403,676 which are hereby incorporated
by reference; fibrous material and one or more forms of
surface-modifying particles bonded thereto as set forth in

Nanoparticles assist cement formulation, reinforcing and
strengthening the interstitial domains within the composition,
obtaining radiopacity when not obtained via the macrofiller,

which is hereby incorporated by reference; densified and 55

--

I

2

Vickers microhardness 6.2 GPa (739 + 22 kg/mm.)

U.S. Pat. No. 6,270,562 which is hereby incorporated by 60 and hardening the surface against wearby increasing the filler

reference; polyhedral oligomeric silsesquioxane fillers as set Volume concentration. While spherical or irregular nanopar
forth in U.S. Pat. No. 6,653,365 which is hereby incorporated ticles are used in current formulations, whisker/nanorods
by reference; nanostructures such as POSSTM (polyhedral and/or clay platelets may also be used for interstitial strength
oligomeric silsesquioxane) Supplied by Hybrid Plastics; and ening of the macroparticle filled composite where obtained at
combinations of all the fillers mentioned. Preferred fillers 65 low filler volume loading. An increased aspect ratio is impor
include titanium oxide and/or calcium phosphate since these tant to mechanical strength, minimization of crack initiation,
materials help promote mineralization and bone adhesion. and can Support mineralization by osteoblast cells though
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spherical or irregular nanoparticles that can also be utilized to
reinforce the interstitial composite so long as a suitable Sur
face modification or coupling agent is utilized to strengthen
bone across the polymer-particle interface. Clay/nanowhis
ker/nonrod dimensions are preferred that have aspect ratios
greater than 10:1 up to about 100:1. Clays include montmo
rillonites and nanowhisker/nanorod includes boehmite, alu

mina, Zirconia, yttria-Stabilized Zirconia, titania, calcium
phosphate, or hydroxyl apatite.
Surface modifications can be used to control interparticle
association, dispersion viscosity, and reactivity with the Sur
rounding matrix. In one aspect, nanospheres or nanofillers,
typically up to 500 nm in length and 30 nm in diameter may
be used. Normal, glass filled systems can also be used for
dispersion quality, flexural strength, hardness, internal poly
merization stress, efficiency of cure, and cell toxicity of the
resulting composite. Compositions of the nanofibers include
alumina nanospheres and nanorods, which have produced
improved tensile and flexural strength. While alumina has
provided remarkable property improvements, Zirconium-yt
trium oxide fiber synthesis, whose fibers have better pH sta
bility compared to alumina, may also be used. Nanorods will
be synthesized via gel formation followed by chemically
templating in conventional oven or by autoclave, as appropri
ate for the desired geometry.
Montmorillonite clays are the most common member of
the Smectite clay family having plate-like primary particles
that possess an anionic Surface with ionically bound cations to
maintain Surface charge neutrality. Natural montmorillonite
clay has sodium counterions on the Surface; however, these
Sodium atoms can be ion-exchanged with other inorganic or
organic ions to change the surface chemistry of the clay
particles. In addition, natural montmorillonite clay particles
are stacked upon one another due to the charge-charge inter
action between the clay platelets. Once the counterion is
exchanged for an organic ion or group, the replacement facili
tates the separation of the clay lattice, especially when pen
etrated by Solvents, monomer or polymer chains, called inter
calation. The particles may then be further dispersed into
discreet nanoplatelets resulting in what is called an exfoliated
clay material. Upon synthesis of exfoliated structures, large
mechanical property improvements of a composite compared
to neat polymer properties are obtained at rather low clay

10

15

25

30

35

40

45

used to contain and act as carriers for antibiotics. Other com

ponents of the composites that could be delivered within the
hydroxyapatite microspheres include growth factors such as
bone morphogenetic proteins (“BMPs), cartilage-derived
morphogenic proteins (“CDMPs'), collagen, or small mol
ecules that are being developed to promote bone growth
through blood vessel formation. In one aspect, the growth
factor is selected from the group consisting of TGFB1,
TGFB2, TGFB3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6,

50

55

BMP-7, BMP-8, BMP-9, CDMP-1, CDMP-2, or CDMP-3.

For silorane composites, good interfacial properties
between polymer resin and fillers improve composite prop
erties and performance. There are variables of group density
and structure, which affect Surface wetting, reactivity, inter
facial structure, and composite strength. The inclusion of a
Surface coupling agent or ligand increases the critical con
centration of particle fillers that can be added by enhancing
Surface wetting and dispersion viscosity. Interfacial proper
ties are even more critical since the intended application
requires immersion within a plasticizing, high-moisture envi

merization stress of the total formulation.

Various TOSUs are set forth in Chappelow, U.S. Published
Patent Application No. 2007/0072954; Chappelow et al., U.S.
Pat. No. 6,825.364; Chappelow et al., U.S. Pat. No. 6,653,
486; Chappelow et al., U.S. Pat. No. 6,658,865; Byerley et al.,
U.S. Pat. No. 5,556,896; Guest, U.S. Pat. No. 3,023,2221;

filler concentration levels.

Such fillers include, but are not limited to, a hydroxyapatite
in the form of hollow microspheres or biocompatible, biode
gradable glass. The microspheres of hydroxyapatite could be
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ronment. Interfaces between filler and resin matrix are prime
locations for weakening through ingress of moisture. How
ever, interfaces can be strengthened through surface modifi
cation of fillers resulting in greater mechanical properties to
enable not only interaction, but also reaction with the sur
rounding polymer matrix, including chain extension,
between filler and polymer matrix. Several types of surface
modifications may be used to improve strength through
development of covalent interface architectures during cure.
Surface modifications are produced through exposure to
dilute solutions to prevent multi-layer, weak, adsorbed struc
tures and provide better ligand access to filler surfaces. After
washing particles thoroughly of excess reagent, groups are
quantified by thermogravimetric analysis (TGA) for com
parison to bare particles. Fourier transform infrared spectros
copy (FTIR), X-ray photoelectron spectroscopy (XPS), and
Surface density calculated from weight loss using known
particle Surface area and correcting for bulk and adsorbed
water loss is used to analyze the filler Surface coating. Surface
tension and wetting of filler powders is readily measured
using tensiometry through the Washburn equation.
The filler typically is about 0, 5, 10, 15, 20, 25, 30, 40, 45,
50, 55, 60, or 70 wt % (or some range therebetween) of the
biomaterial composition.
TOSUs and TOSU-Like Compounds
TOSUs may optionally be added to the biomaterial com
positions of the present invention. The TOSUs may be clas
sified as 1,5,7,1'-tetraoxaspiro5.5undecanes or 2.4,8,10-tet
raoxaspiro5.5undecanes. The TOSUs may or may not have
a silicon-containing moiety. The TOSUs are preferably a
potential expanding monomer type. By using the TOSUs, the
composition has the potential of reducing the amount of poly

Sadhir & Luck, Expanding Monomers. Synthesis, Character
ization, and Applications, CRC Press, Boca Raton, Fla.
(1992); Rokicki, Aliphatic cyclic carbonates and spiroortho
carbonates as monomers, Prog. Polym. Sci. 25 259-342
(2000): Imai et al., JP 28196665B2; and Porret et al., JP
03099086; which are all incorporated by reference. An
important synthetic precursor is 3,9-diethyl-3.9-bis(ally
loxymethyl)-1.5.7.11-tetraoxaspirol5.5undecane (DE
BAOM-1.5.7.11-TOSU), and is a six-member ring spiroor
thocarbonate that is a liquid at room temperature. The vinyl
groups on this molecule permit the addition of a wide variety
of reactive and unreactive functionalities by electrophilic and
radical means. These functionalities can be both symmetric
and asymmetric.
In one aspect of the present invention, TOSUs according to
Formulas A1 or A2 may be utilized in the biomaterial com
positions:

60

(A1)
65
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-continued
R1 O

O

O

O

R3

six X).

(A2)
5

20
For example, in one aspect, the TOSUs are selected from
the group consisting of the following compounds:
3,9-Diethyl-3.9-bis(allyloxymethyl)-1.5.7.11-tetraoxas
pirol5.5undecane (DEBAOM-1,5,7,11-TOSU) (Example 1
of Chappelow, U.S. Published Patent Application No. 2007/
0072954)

wherein RandR are independently is alkyl, aryl, aralkyl,
or hydrogen; and
CH5
wherein R and Rare independently alkenoxy, alkenoxy 10
alkyl, or silicon-containing moiety selected from alkylsilyl,
Hic=g1
No
O O
H
arylsilyl, arylalkylsilyl, alloxysilyl, aryloxysilyl, arylalkox
ysilyl alkylsiloxy, arylsiloxy, arylalkylsiloxy, alkoxysiloxy,
aryloxysiloxy, arylalkoxysiloxy, alkylsilylalkyl, arylsilyla
O
O
CECH
N1
2
lkyl, arylalkysilylalkyl, alkoxysilylalkyl, aryloxysilylalkyl, 15
arylalkoxysilylalkyl, alkylsiloxyalkyl, arylsiloxyalkyl, aryla
CH5
lkylsiloxyalkyl, alkoxysiloxyalkyl, aryloxysiloxyalkyl, ary
lalkoxysiloxyalkyl, alkylsilylalkoxy, arylsilylalkoxy, aryla
9-Bis(3-trimethylsilylpropyl)-1.5.7.11-tetraoxaspiro5.5
lkylsilylalkoxy, alkoxysilylalkoxy, aryloxysilylalkoxy,
arylalkyloxysilylalkoxy, alkylsiloxyalkoxy, arylsiloxy 20 undecane (BTMSP-1,5,7,11-TOSU) (Example 2 of Chap
alkoxy, arylalkylsiloxyalkoxy, alkoxysiloxyalkoxy, arylox pelow, U.S. Published Patent Application No. 2007/0072954)
ysiloxyalkoxy, and arylalkoxysiloxyalkoxy.
In another aspect, the TOSUs are characterized by Formu
las A1 or A2 wherein R and Ra are independently alkylsily
lalkyl or alkylsiloxyalkyl. In one preferred aspect, RandR 25
are independently trimethylsilylpropyl, trimethylsilylethyl,
triethylsilyipropyl, or triethylsilylethyl.
In still another aspect, the TOSU compounds according to
Formula A1 or A2 are characterized such that R and R are
independently is alkyl, aryl, aralkyl, or hydrogen; and 30
wherein R and Ra are independently alkenoxyalkyl or alkyl
3,9-Bis(allyloxymethyl)-2,4,8,10-tetraoxaspiro5.5unde
silylalkyl. In still another aspect, RandR are independently cane (BAOM-2,4,8,10-TOSU) (Example 3 of Chappelow,
alkenyloxyalkyl selected from —(CH), O-(CH) - U.S. Published Patent Application No. 2007/0072954)
CH=CH, and wherein mand n are independently 0, 1, 2, 3,
4; or alkylsilylalkyl selected from trimethylsilylpropyl and 35
trimethylsilylethyl.
O
In another aspect, the TOSU compounds according to the
H
Formula A2 are characterized such that R and R are inde
O
O
pendently alkyl, aryl, aralkyl, or hydrogen; and wherein R
H
and Ra are independently alkenyl, alkenoxy, alkenoxyalkyl, 40
or silicon-containing moiety selected from alkylsilyl, arylsi
--ON1 CECH2
lyl, arylalkylsilyl, alloxysilyl, aryloxysilyl, arylalkoxysilyl,
alkylsiloxy, arylsiloxy, arylalkylsiloxy, alkoxysiloxy, arylox
ysiloxy, arylalkoxysiloxy, alkylsilylalkyl, arylsilylalkyl, ary
3,9-Bis(2-trimethylsilylethyl)-2,4,8,10-tetraoxaspiro5.5
lalkysilylalkyl, alkoxysilylalkyl, aryloxysilylalkyl, aryla 45 undecane (BTMSE-2,4,8,10-TOSU) (Example 4 of Chap
lkoxysilylalkyl,
alkylsiloxyalkyl,
arylsiloxyalkyl, pelow, U.S. Published Patent Application No. 2007/0072954)
arylalkylsiloxyalkyl, alkoxysiloxyalkyl, aryloxysiloxyalkyl,
arylalkoxysiloxyalkyl, alkylsilylalkoxy, arylsilylalkoxy, ary
lalkylsilylalkoxy, alkoxysilylalkoxy, aryloxysilylalkoxyary
O
O
lalkyloxysilylalkoxy, alkylsiloxyalkoxy, arylsiloxyalkoxy, 50
H
H. H.
(CH3)Si-C - 2
C - C -Si(CH3)
arylalkylsiloxyalkoxy, alkoxysiloxyalkoxy, aryloxysiloxy
alkoxy, and arylalkoxysiloxyalkoxy.
O
O
In another aspect, the TOSU compounds according to the
Formula A1 or A2 are characterized such that R and R are
independently alkyl, aryl, aralkyl, or hydrogen; and wherein 55 3.3-Diethyl-11, 12-epoxy-1,5,7,16-tetraoxadispiro
5.2.5.2 hexadecane (DECHE-1,5,7,11-TOSU) (Example 5
R and Ra are independently alkenyl, alkenoxyalkyl, and
alkylsilylalkyl. In still a further aspect, R and R are inde of Chappelow, U.S. Published Patent Application No. 2007/
pendently alkenyl selected the group consisting of —(CH), 0072954)
—CH=CH, and wherein n is independently 0, 1, 2, 3, 4; or
alkenyloxyalkyl selected from —(CH), O—(CH2)— 60
CH=CH, and wherein mand n are independently 0, 1,2,3,
O O
Et
4; or alkylsilylalkyl selected from trimethylsilylpropyl and
trimethylsilylethyl.
O
O O
In another aspect, R. R. R. and Ra are independently
selected from the group consisting of alkyl, olefin-terminated
alkyl, olefin-terminated alkyl ether, trimethylsilyl alkyl ether,
and cyclohexyl.

--

g-ror

A XXX.

H
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3,9-Diethyl-3.9-bis(3-trimethylsilylpropyloxymethyl)-1,
5,7,1'-tetraoxaspiro5.5undecane (DEBTMSPOM-1,5,7,
11-TOSU) (Example 6 of Chappelow, U.S. Published Patent
Application No. 2007/0072954)

22
TOSUs (or compounds having analogous ring systems like
the compounds shown below) to the silorane and/or as filler
particle Surface treatment should improve the mechanical
properties of the silorane composite. The synthesis of (9.9diethyl-1,5,7,11-tetraoxaspiro5.5undecan-3-yl)methyl)tri
methoxysilane (“1TOSU) and (3-(9,9-diethyl-1,5,7,11-tet
raoxaspiro5.5undecan-3-yl)propyl)trimethoxysilane
(“3TOSU) is shown in the schemes below.

(HCs1\1\o
On 1-Si(CH3)3

10

Scheme 1: Synthesis of 1-TOSU

CH5

(9-Allyloxymethyl-9-ethyl-1,5,7,11-tetraoxaspero 5.5
undec-3-ylmethyl)-dimethylphenyl-silane (AOME-TOSU
MDMPS)

Step-1
RNC
15 C

C

AcONa

3-chloro-2-

Toluene

(chloromethyl)-1propene

Step-2

/

NaOH

AcO

Co

OAc

------e-

MeOH-HO

3-acetoxy-2(acetoxymethyl)-1propene

25

RSnBu

Step-3

Bu2SnO
HO

Methyl 2-(7-Oxabicyclo4.1.0 hept-3-yl)ethyl-phenyl 3
(3,9.9-triethyl-1,5,7,1'-tetraoxaspiro5.5undec-3-yl
methoxy)propylsilane (MOB-HEP-TETOSU-MOPS)

OH

/

--

2-methylene-1,3propanediol

30

O

2,2-Dibutyl-5methylene
1.3.2di-oxastanninane
Product A
O

OH

C2H5

Step-4
CSCl

35

OH

O

CH5

O

O O

2,2-Diethyl-

C6Hs

O

t

s

C

1n H1 no.1"Nii
H2 CH

CHs H2

)= S
O

5,5-Diethyl-1,3dioxane

propane-1,3-diol

t

2-thione
Product B

O

40
A

--

B

Step-5

--

O

For biomaterial compositions containing fillers, stress-re
ducing monomers like TOSUs may be used for surface modi
fication through the attachment of a Surface-reactive ligand
group, Such as a pendant silyl or phosphate, that is reactive
with the filler oxide surface. The organic moiety provides
wetting and dispersion, interfacial (cure) reactivity, and inter
facial strength properties while adding the potential to reduce
internal stress in the composite. Since group length has a
direct effect on interfacial bond and thus composite strength,
the tether length between the reactive group and the surface
active ligand is one design aspect may be considered. See
Wang et al., Dharani L. R. Effect of interfacial mobility on
flexural strength and fracture toughness of glass/epoxy lami
nates, Journal of Materials Science 34(19) 4873-4882
(1999); Schuman et al., Surface modified nanoparticles as
enhanced fillers for dental polymer-particle composites, J
Dent Res 89 (2010); Schuman et al., Improved dielectric
breakdown strength of covalently-bonded polymer-particle
nanocomposites, Composite Interfaces, 17, 719-731 (2010).

For example, for 3-(9,9-diethyl, 1.5.7.11-tetraoxa-spiro (5.5)
undec-3-yl)propyl-trimethoxy-silane ("3TOSU”), a surface
group density of about 26 A2/group was obtained in reacting

with glass particles or alumina nanorods, measured through
TGA and also observed through XPS. Thus, addition of

O

X

O
45

Step-6

O

R or Pt
-e-

3,3-Diethyl-9-methylene-1,5,7,
11-tetraoxa-spiro5,5undecane

HSi(OMe)
O

O

- X. X

50

(9.9-Diethyl-1,5,7,11-tetraoxa
spiro5.5undec-3-ylmethyl)trimethoxy-silane

55

Scheme 2: Synthesis of 3-TOSU

/

60

Step-1
LAH

/-

O

\

65

Allyl diethylmalonate

He
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-continued

-continued
Step-2
Bu2SnO

HO

OH

2-trimethoxysilylethyl-1,4,6trioxaspiro4.6 undecane

2-Allyl-1,3-propanediol
O

V

SnBu2

o

10

/

O

Scheme 4

5-Allyl-2,2-dibutyl-1,3,2)
dioxastanninane
Product A
15

OH

Step-3
CSCl

O

O

O

1. 5'--

S

O --

-e-

OH

O

2,2-Diethyl-propane-

3-glycidoxypropyltrimethoxysilane

5,5-Diethyl-1,3dioxane

1,3-diol

2-thione

BFOEt
CHCl2

Product B
A

--

B

He

Step-4

O

He

caprolactone
O

O

25

O

Step-5

O

R or Pt
o

He

O

O

HSi(OMe)
30

O

(H3CO)Si

\

2-trimethoxysilylpropyloxyethyl
1,4,6-trioxaspiro4.6 undecane

O

X
O

re
O

O O

9-Allyl-3, 3-diethyl
1,5,7,11-tetraoxia-spiro
5,5undecane

/

X

O

35

3-(9.9-Diethyl-1,5,7,11-tetraoxia
spiro5.5undec-3-yl)-propyl-trimethoxy-silane

The TOSUs (or TOSU-like compounds) preferably com
prises about 0 to 25% by weight of the biomaterial composi
tion. For example, the TOSUs may comprise about 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 wt %

(or some range therebetween) of the biomaterial composi
tion.
40

Scheme 3: Non-TOSU monomers of similar reactivity and properties
as TOSU
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50
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O
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2-chloromethyl-1,4,6trioxaspiro4,6undecane

O

55

2-methylene-1,4,6trioxaspiro4,6-undecane

60

O

OX

O

r --

2-methylene-1,4,6trioxaspiro4,6-undecane

M

O-SH

/ YTrimethoxysilane

Pt

e
65

In another aspect, filler(s) are combined with one or more
TOSUs. The optional filler and optional TOSU is preferably
selected from the group consisting of (1) crushed light initi
ated SilMix (pre-polymerized SilMix); (2) DY5-yttria alu
mino-silicate; 15.0 wt %YO, 5.0 wt % Al-O, and 80 wt %
SiO2; (3) DY5 modified with 2-(3,4-epoxycyclohexyl)-ethyl
trimethoxysilane (ECHE); (4) DY5 modified with 3-(gly
cidyloxy)-propyl-trimethoxysilane (GPS); (5) DY5 modified
with 3TOSU (3-(9,9-diethyl-1,5,7,11-tetraoxaspiro5.5un
decan-3-yl)propyl)trimethoxysilane; (6) DY5 modified with
1TOSU ((9,9-diethyl-1,5,7,1'-tetraoxaspiro5.5undecan-3
yl)methyl)trimethoxysilane; (7) M12-barium boroalumino
silicate; 54.5 wt % SiO, 5.9 wt % Al-O, 10.5 wt % BO,
and 29.1 wt % BaC); (8) M12 modified with ECHE ethylcy
clohexylepoxide; (9) M12 modified with 3TOSU (3-(9.9diethyl-1,5,7,11-tetraoxaspiro5.5undecan-3-yl)propyl)tri
methoxysilane; (10) M12 modified with 1TOSU (9.9diethyl-1,5,7,11-tetraoxaspiro5.5undecan-3-yl)methyl)
trimethoxysilane; (11) clays, montmorillonite plates of
aspect ratio between about 100 to 300, surface modified with
organic ammonium ions containing epoxy, hydroxyl, ether,
ester, phosphate, allyl or vinyl functional groups, or silanes
(trichloro, trimethoxy, triethoxy, dichloromethyl,
dimethoxymethyl, diethoxymethyl, chlorodimethyl, meth
oxydimethyl, or ethoxydimethyl) containing a pendant
epoxy, hydroxyl, ether, ester, phosphate, allyl or vinyl func
tional group; and (12) nanoparticles as spherical, nanofiber,
nanowhisker, or nanorod—especially gamma aluminum,
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hydroxyapatite, calcium phosphate, Zirconium, or titanium,
with aspect ratio in the range of about 1 to 200, preferably
between 1 and 20, neat or surface modified with organosi
lanes (trichloro, trimethoxy, triethoxy, dichloromethyl,
dimethoxymethyl, diethoxymethyl, chlorodimethyl, meth
oxydimethyl, or ethoxydimethyl) containing a pendant
epoxy, hydroxyl, ether, ester, phosphate, allyl or vinyl func
tional group or Surface modified with organophosphates con
taining a pendant epoxy, hydroxyl, ether, ester, allyl or vinyl
functional group, including 1 TOSU, 3TOSU, or a TOSU
phosphate surface active, ligand groups.
The following examples are offered to aid in understanding
the invention and are not to be construed as limiting the scope
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TABLE 3-continued
Exemplary P1 formulations
SiMix
5

10

thereof.
15

EXAMPLE1

Preparation of Exemplary Bone Cement
Compositions
In this example, various biomaterials useful as bone
cement compositions were prepared. All samples were pre
pared at room temperature (about 20°C.) under yellow light
(for the light-initiated systems and the dual chemical/light
curing systems, but not the chemical curing systems) in order
to prevent premature polymerization. The samples will be
referred to as either neat resins (no filler) or filled resin (may
include one or more fillers).
Each of the bone cement compositions comprised two

silorane monomers, bis(2-(3{7-Oxabicyclo[4.1.0]hepty1})

ethylmethylphenyl silane (PHEPSI) and 2,4,6,8-tetrakis(2(7-Oxabicyclo4.1.0 heptan-3-yl)ethyl)-2,4,6,8-tetramethyl
1.3.5.7.2,4,6,8-tetraoxatetra-silocane (CYGEP). Both
PHEPSI and CYGEP were prepared using adapted proce
dures and used at purities greater than 95.8% as determined

25
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SiMix

DYS

PIH

LMC

O.S472
O4972
O.S478
O4483
O4(OOO
O4483
O4472
O4960
O4472
O5466
O4483
O4483
O446O
O4(OOO
O4978
O4484
O.S478
O4475
O4(OOO
O4984
O.S472
O4472
O4(OOO
O446O
O.4722
O4483
O4984
O4484
O4960
O4484
O4972

O3SOO
O4(OOO
O3SOO
O.3994
O3984
O.3994
O3SOO
O3SOO
O3SOO
O3SOO
O.3994
O.3994
O4SOO
O4SOO
0.3747
O4SOO
O3SOO
O4247
O3984
O3SOO
O3SOO
O3SOO
O.3960
O4SOO
0.3747
O.3994
O3SOO
O4SOO
O3SOO
0.3747
O4(OOO

O.1000
O.1000
O.1000
O.1494
O.2OOO
O.1494
O.2OOO
O.1SOO
O.2OOO
O.1000
O.1494
O.1494
O.1000
O.1472
O.1247
O.1000
O.1000
O.1247
O.2OOO
O.1500
O.1000
O.2OOO
O.2OOO
O.1000
O.1497
O.1494
O.1500
O.1000
O.1SOO
O.1747
O.1000

OOO2O
OOOO8
OOOO8
OOO14
O.OOO8
OOO14
O.OO2O
O.OO2O
O.OOO8
OOO14
OOO14
OOO14
OOO2O
O.OO2O
O.OO17
OOOO8
OOOO8
O.OO17
O.OOO8
OOOO8
OOO2O
O.OOO8
O.OO2O
OOO2O
O.OO17
OOO14
OOOO8
OOOO8
O.OO2O
O.OO11
OOOO8

O.OOO8
O.OO2O
OOO14
O.OO14
O.OOO8
O.OO14
O.OOO8
O.OO2O
O.OO2O
O.OO20
O.OO14
O.OO14
O.OO2O
O.OOO8
O.OO11
O.OOO8
OOO14
O.OO14
O.OOO8
O.OOO8
O.OOO8
O.OO2O
O.OO2O
O.OO2O
O.OO17
O.OO14
O.OOO8
O.OOO8
O.OO2O
O.OO11
O.OO2O
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P2 DY5 mod ECHE (“P2A) comprises (A) co-mono
mer system Sil Mix (1:1 by weight of PHEPSI and CYGEP),
between about 35 to 55 wt %, ’%; (B) Lamoreaux's catalyst,
between about 0.3 to 0.8 wt %; (C) a light initiation system
comprising about 3.0 wt % p-(octyloxyphenyl)phenyliodo

40

phorquinone, and about 0.15 wt % ethyl 4-dimethylami
nobenzoate; and (D) a filler ECHE modified DY5, between

by "H NMR spectroscopy. See Aoki, U.S. Pat. No. 6.255.428;

Crivello, The Synthesis and Cationic Polymerization of Mul
tifunctional Silicon-Containing Epoxy Monomers and Oligo
mers, J. Polym. Sci. Part A: Polym. Chem.32 683-697 (1994).
P1 comprises a chemical cure system comprising an organo
metallic catalyst and an accelerator. P2 comprises a dual
chemical/light cure system comprising and organometallic
catalyst and a photoinitiation system.
P1 comprises (A) co-monomer system SilMix (1:1 by
weight of PHEPSI and CYGEP), between about 40 to 55 wt
%; (B) photoacid p-(octyloxyphenyl)phenyliodonium
hexafluoroantimonate, between about 0.05 to 0.20 wt %; (C)
Lamoreaux's catalyst, between about 0.09 to 0.2 wt %; (D)
filler DY5, between about 10 to 20 wt %; and (E) filler crushed
Sil Mix, between about 25 to 50 wt %. The following table
includes several exemplary bone cement compositions that
were prepared.

Pre-polymerized

Silorane Co-Monomer

nium hexafluoroantimonate, about 1.0 wt % cam

about 45 to 65 wt %.

45

P2 DY5 mod 3TOSU (“P2B) comprises (A) co-mono
mer system SilMix (1:1 by wt of PHEPSI and CYGEP),
between about 35 to 55 wt %; (B) Lamoreaux's catalyst,
between about 0.3 to 0.8 wt %; (C) a light initiation system
comprising about 3.0 wt % p-(octyloxyphenyl)phenyliodo
nium hexafluoroantimonate, about 1.0 wt % cam

50

phorquinone, and about 0.15 wt % ethyl 4-dimethylami
nobenzoate; and (D) a filler 3TOSU modified DY5, between
about 45 to 65 wt %.

TABLE 3
55

Exemplary P1 formulations

P2 DY5 mod 1TOSU (“P2C) comprises (A) co-mono
mer system SilMix (1:1 by wt of PHEPSI and CYGEP),
between about 35 to 55 wt %; (B) Lamoreaux's catalyst,
between about 0.3 to 0.8 wt %; (C) a light-initiation system
comprising about 3.0 wt % p-(octyloxyphenyl)phenyliodo
nium hexafluoroantimonate, about 1.0 wt % cam

SiMix

Pre-polymerized

Silorane Co-Monomer

SiMix

DYS

PIH

LMC

OS466
O.4000
O.4000
O.4000
O.4722
O4242
O4472
O.4000
O.4000

O.3SOO
O4SOO
O4SOO
O.3960
O.3997
O4118
O.3SOO
O.3960
O4SOO

O.1OOO
O.1472
O.1472
O.2OOO
O.1247
O.1618
O.2OOO
O.2OOO
O.1472

O.OO14
O.OOO8
O.OOO8
O.OO2O
O.OO17
O.OO11
O.OO2O
O.OO2O
O.OO2O

O.OO20
O.OO2O
O.OO2O
O.OO2O
O.OO17
O.OO11
O.OOO8
O.OO2O
O.OOO8

phorquinone, and about 0.15 wt % ethyl 4-dimethylami
nobenzoate; and (D) a filler 1TOSU modified DY5, between
60

65

about 45 to 65 wt %.

The components of the exemplary inventive formulations
are mixed together in order to indicate polymerization. In a
preferred aspect, all of the components except the Lamor
eaux's catalyst are first mixed together in a Suitable mixing
device (such as a mixing cup). The desired amount of Lam
oreaux's catalyst is added and then the combined mixture is
further mixed.
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For comparative purposes, in some instances, the inventive
formulations were compared to those of conventional
PMMA-based Simplex P Bone Cement (Stryker Homedica
Osteonics). The first powder component is a mixture of poly
methyl methacrylate (PMMA) (15.0%), methyl methacry
late-styrene-copolymer (75.0%), and barium sulfate (10.0%).
The second component of Simplex P bone cement is a liquid
monomer containing methyl methacrylate monomer
(97.4%), N,N-dimethyl-p-toluidine (2.6%) and hydro
quinone (7515 ppm). The two components are mixed at a ratio
of 2 g powder to 1 mL liquid monomer to initiate the free
radical polymerization process.
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(VitroCom, Mountain Lakes, N.J.) coated with silicone spray
mold release (Mark V Laboratory, East Granby, Conn.) as per
ISO specification 4049. A pipette was used to fill the molds
with resin. The specimen was irradiated (12 mm diameter tip,

450 mW/cm (Cure Rite, Dentsply Caulk, Milford, Del.) at a

distance of 3 mm) using a dental curing lamp (XL3000; 3M,
St. Paul, Minn.) for two minutes along the top surface at three
consecutive regions for 40 seconds each, 40 seconds in a
scanning motion along the bottom of the glass mold, and then
10
the specimen was removed from the glass. The method of
photoinitiating specimens and induction of any overlapping
regions have been shown to not have an effect on flexural
properties. The specimens were stored in phosphate buffered
EXAMPLE 2
15 saline (PBS), at 23+1° C., for 24 hours, after which, the
specimen was loaded, until fracture, at a displacement rate of
Mechanical Testing
3.7 mm/min in a four-point bend fixture with a support span
of 20 mm on a BOSE mechanical tester (EnduraTEC ELF
Polymerization Stress
The bone cement compositions of the present invention 3300, Eden Prairie, Minn.). Specimens with visible surface
will be tested for polymerization stress. Two glass rods are flaws, bubbles, or undistributed filler particles were excluded
placed 1 mm apart on the Bose mechanical testing instrument. from the study. The resulting stress-strain curve was used to
Strain during testing will be held constant, less than 1.0 Lim determine flexural strength (O) and flexural modulus of elas
deflection, during polymerization. The peak load during ticity (E). The following two equations were used to calcu
polymerization will be used to calculate polymerization lated stress (Eq. 1) and strain (Eq2). The resulting stress-strain
curve was used to determine flexural yield strength and flex
stress as generally described in Eick et al., Properties of 25 ural
modulus of elasticity
silorane-based dental resins and composites containing a
stress-reducing monomer, Dent Mater 23(8) 1011-1017
(2007), which is incorporated by reference.
loadX load span
O
Maximum Exotherm Temperature
specimen
width
x (specimen thickness)
Exotherm temperature was measured using a K-type ther 30
5.4X
displacementX
specimen thickness
mocouple (Omega, Stamford, Conn.) affixed to a glass slide
--- load span?
and slightly bent so that the tip of the thermocouple was
positioned in the center of an acetal resin (Delrin R) washer
(McMaster-Carr, Aurora, Ohio), which was also affixed to the Compressive Strength
glass slide with lab tape. Each composite formulation (0.6 g) 35 The bone cement compositions of the present invention
was mounded to completely cover the tip of the thermo will be tested for compressive strength. Cylindrical speci
couple. The sample was then irradiated (12 mm diameter tip, mens (6 mm diameterx12 mm height) were formed in a metal
450 mW/cm (Cure Rite, Dentsply Caulk, Milford, Del.) at a
coated with silicone spray mold release as per ISO
distance of 3 mm) using a dental curing lamp (3M XL3000, mold
specification
4049. A pipette was used to fill the mold and
St. Paul, Minn.) for two minutes. Specimens were inspected 40 composite formulations
were either light-irradiated for 2
after testing, and results were excluded from further study if minutes at each end of the cylinder for photoinitiated mate
the tip contacted the glass slide or was not entirely covered rials, or allowed to polymerize for 30 minutes for chemically
with the composite. Temperature data were recorded using a initiated materials. The cylinders were then removed from the
data logger (OM-PLTC, Stamford, Conn.) at 1 Hz for 30 molds and stored in PBS, at 23+/-1° C., for 24 hours, after
minutes post-irradiation. Handling time was defined as the 45 which specimens were loaded until fracture at a displacement
time between initiation and when the exotherm reached half
rate of 20 mm/min between two smooth platens in compres
of its peak temperature.
sion. Specimens with visible surface flaws, bubbles, or undis
Handling Properties/Handling Time
tributed
particles were excluded from the study. The
The handling properties generally refer to the time from resultingfiller
peak
load prior to failure was used to calculate
addition of catalyst or irradiation until one cannot manipulate 50 compressive strength.
the material. That is, handling time refers to the length of time
the material can be manipulated between mixing and poly
TABLE 4
merization to allow for placement in the body. Bone cement
consistently reaches dough time around 1.9 mm penetration
Range of properties for P1 and P2 (P2A. P2B. P2C).
(about 9 minutes post-mixing). Curing time occurs when 55
Desired ISO 5833
penetration is 0.0 mm (about 15 minutes).
P1
P2
properties Standard
Handling properties will be measured with a penetrometer.
s1.0
Timing will start as the monomer (0.75 g) is mixed and placed Polymerization stress
(MPa)
in an aluminum washer (12.7 mm diameter, 2.5 mm deep). Exothermicity
(C.)
25-30
26 - O.S
s:45
s90
Penetration measurements (mm) will be taken periodically 60 Handling time (mins)
8-10
8-10
s20
3-15
with a mass of 49.2 g applied to the penetrometer cone for 5 Intrusion (mm)
e2
15-17 2.2-3.5
e1.8
seconds. This test will provide viscosity, and curing, dough, Flexural modulus (GPa.)
Flexural strength (MPa)
22-33
25-60
eSO
and manipulation time.
Compressive strength
68-77
ef)
Flexural Strength and Modulus
(MPa)
The bone cement compositions of the present invention 65 Cytotoxicity (% cell death) 1796
s2O%
will be tested for flexural strength. Flexural specimens (25
mmx2 mmx2 mm) were formed in borosilicate glass tubes
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similar for all chemically cure resins, their decrease in cell
numbers seem to be an effect of cell growth inhibition rather
than cell death. Growth inhibition may have occurred because
cells did not attach well to the polymer surfaces.

EXAMPLE 3

Cytotoxicity on Neat Dual Cure SilMix
In this example, the objective was to determine the bone
cell growth on chemically cured silorane resins using a poly
merization system containing acetic acid as a proton donor
plus exposure to halogen lamp. The compositions are
described in Table 5. Solid resin discs (9 mm diamx0.5 mm
thick) (n=12) were yellow and transparent. Discs passed the
GNT and were delivered in a closed plastic container. The
discs were yellowish transparent and were used as received
(no UV light sterilization as in previous experiments). Discs
were placed into 48-well plate (n=4), pre-washed in growth
media for 1 h at 35°C./5% CO. Then the wash media was
replaced with 0.5 mL MLO-A5 cell suspension containing

5

EXAMPLE 4
10

Cytotoxicity of Neat Chemically Initiated Silorane
Using LMC
15

In this example, the Lamoreaux's catalyst-cured resin (Sil
Mix CC) was tested for in vitro biocompatibility and was
found to be comparable to the light cure silorane resin (SilMix
LC). The formulations investigated are shown in the follow
ing Table 7.

2x10 cells. After 24 hours and 48 hours in culture, cell
viability was measured using the MTT assay and the number
of live and dead cells was measured using the TBE assay. The
results are summarized in Table 6 and FIG. 1.
TABLE 5

Dual Chemical/Light Cured Silorane Resins Formulation
Compared to Light Cured Silorane
Chem ID

Bio ID

SM17-DVA
SM17-DVB
SM17-DVC
SM17 PIHB

DCA
DCB
DCC
Light initiated

SiMix

AA

PIH

CPQ

3g
3g
3g
3g

0.024 g
0.048 g
0.096 g
0g

0.024 g
0.048 g
0.096 g
0.094g

0.008 g
0.016 g
0.032 g

0.031 g 0.005 g

used as control

AA= acetic acid; PIH = p-(octyloxyphenyl)phenyliodonium hexafluoroantimonate; CPQ = camphorquinone;
EDMAB = ethyl p-dimethylaminobenzoate.

TABLE 6

Live and Dead Cell Numbers and Calculated Percent in the Trypan Blue Test.
24h live cells

ID
control
DCA
DCB
DCC
PIH (light)

# cells x 10
26 - 1
43
93
103
15 - 4

24h dead cells

48 h live cells

48 h dead cells

% it cells x 10

% it cells x 10

% # cells x 10'

89
43
68
75

11
57
32
24

89
65
66
81

86

3- 1
52
4+1
3- 1
2 - O.S

14

519
82
93
164
24 6

89

The MTT results indicate that dual cured resins (DCB and
DCC) produced adherent cell viability similar (p-0.05) to the
photoinitiated silorane resin PIH in 24 hours (FIG.1, panele)
and 48 hours (FIG. 1, panel f) cultures. However, in the
Trypan blue assay (Table 6), only the dual cured resin DCC
produced live cell numbers (adherent and non adherent) simi
lar (p-0.05) with the photoinitiated silorane resin PIH in 24
hours (FIG.1, panela) and 48 hours (FIG.1, panelb) cultures.
From the MIT and Trypan blue results, the dual cured resin
DCC is more biocompatible than the others tested and was the
most similar to the photoinitiated silorane PIH. Among the
dual cured resins, the resin DCC contained more polymeriza
tion system (about 7%) than the other two resins (DCB 3.6%
and DCA 1.8%) which used decreasing amounts of acetic
acid (Table 5). It is thought that with more initiator there is
likely more polymerization. Therefore, there would be less
monomer and more reacted polymer resulting in less toxicity.
However, since the dead cells (as number and percent) appear

6- 2
3- 2
51
4+ 1
3- 1

11
35
34
19
10

TABLE 7

50

Chemically cured silorane (SilMix CC) formula compared
to light cured silorane (SIMix LC
55

60

Polymer

PHEPSI
CYGEP

LMC

1:1 (g)

(g)

SiMix LC is

3.00304

control and light

(95.85%)

initiated
SiMix CC

4.OO133

EDMAB

PIH (g) CPQ (g)
O.O940S

O.O3130

(g)
OOO468

(3.005%) (0.99%) (0.153%)
O.OO274 O.OOO148

(99.89%) (0.07%) (0.04%)
LMC = Lamoreaux catalyst;
PIH = p-(octyloxyphenyl)phenyliodonium hexafluoroantimonate;
CPQ = camphorquinone;
EDMAB = ethyl p-dimethylaminobenzoate
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Polymer discs were prepared from both photoinitiated
(LC) and chemically initiated (CC) SilMix. The samples were

US 9, 186,302 B2
31
sterilized on the day of assay using two hour UV light expo
Sure in a tissue culture laminar hood. Then, discs were placed
into 48-well plate (n=3-4), pre-washed in growth media for
one hour at 35° C./5% CO. The wash media was discarded

32
SilMix) or a dental curing lamp 3 times for 20 seconds (pho
toinitiated SilMix). The stabilized bones were stored in a
humidified atmosphere for 24 hours, and then tested biome
chanically. The data (FIG. 3) show that there is no difference
and replaced with 2x10 MLO-A5 cells/0.5 mL. After 24 5 between the photoinitiated and dual cured SilMix group.
hours and 48 hours of incubation, cell viability and prolifera
EXAMPLE 6
tion was measured using the trypan blue method. Another set
of discs was used for extraction of leachables by incubating
the discs for 24 hours in culture media with serum. After 24
Characterization of Flexure Strength and Modulus of
hours, the extracts were transferred to a monolayer of MLO- 10
Neat Bone Cement
A5 cells (seeded the day before). The cells were exposed to
the extracts for 24 hours, after which the cell viability was
As discussed above, the flexural strength and flexural
measured using the MTT assay. Based on the trypan blue modulus results for the P1 system and P2 systems was inves
exclusion assay results, the number of live cells in the wells tigated. The results are illustrated in panelsa and b of FIG. 4.
with the polymer Sil Mix LC and Sil Mix CC were less than 15 More specifically, panel a of FIG. 4 illustrates the flexural
(p<0.05) the control (plastic cell culture wells), while there strength while panelb of FIG. 4 illustrates the flexural modu
was no significant difference in the number of dead cells. The lus
of the P1 and P2 systems compared to a conventional
percentage of live to dead cells with LC and CC SilMix was PMMA
system. P1 (aka BCM52) comprised 50 wt % Sil Mix,
the same as the controls (FIG. 2) showing that the reduction in
cell number was not due to toxicity but was due to reduced 20 0.1 wt % PIH, 0.1 wt % Lamoreaux's catalyst, 35.8 wt %
proliferation. This is most likely due to reduced adherence to pre-polymerized crushed SilMix, and 14 wt % DY5 filler. P2
the polymer Surface as bone cells have been shown to require comprised 39.45 wt % SilMix with a light initiation system
an attachment surface to proliferate. This lack of cytotoxicity (EDMAB 0.15 wt %: CQ 1 wt %; PIH;3 wit%; Sil Mix 95.85
was confirmed in the MTT assay. The Formazan product in wt %), 0.56 wt % Lamoreaux's catalyst, and 59.99 wt %
the presence of extracts from Sil Mix LC (OD=0.954) and 25 3TOSU modified DY5 filler. “P2 W/1TOSU-1’ and “P2
Sil Mix CC (0.96+3) were similar to the controls (0.92+5). w/1TOSU-2 were two separate beams comprising 39.7 wt %
From these results, it is clear that the in vitro cytocompatibil Sil Mix with a light initiation system (EDMAB 0.15 wt %; CQ
ity of the chemical cure SilMix is comparable to the photo
1 wt %; PIH, 3 wt %; Sil Mix 95.85 wt %), 0.3 wt % Lamor
initiated SilMix in the 24 and 48 hour cultures with bone like
eaux's catalyst, and 60.01 wt %1TOSU modified DY5 filler.
MLO-A5 cells.
30
In separate experiments, the flexural strength and flexural
modulus
of two different P1-type of systems (Table 8) was
EXAMPLE 5
investigated, the results of which are shown in FIG. 4 (panels
c and d) and Table 9. It will be appreciated that these inventive
Stabilization of Fractured Excised Femur with
systems are filled systems containing Lamoreaux's catalyst.
Differently Cured Sil Mix Resin

35

In this example, the stabilization effects of a dual chemical/
light cured composition of the present invention was com
pared to that of a conventional light curing system. A halogen
light (100W) at a distance of 18 inches was used to cure the 40
system over a period of about 5 minutes. The dual cure system
comprised (A) co-monomer system SilMix (1:1 by weight of
PHEPSI and CYGEP), 93 wt %; (B) weak Bronstead acid—
acetic acid, 3 wt %, (C) photoacid p-(octyloxyphenyl)phe
nyliodonium hexafluoroantimonate, 3 wt %, and (D) photo- 45
sensitizer, camphorquinone 1 wt %. For comparative
purposes, a light cure system comprising 95.85 wt % SilMix,
3 wt % PIH, 1 wt % camphorquinone, and 0.15 wt % EDMAB

TABLE 8

Exemplary Pll Systems
% Pre

Sample

Total
(g)

%
SiMix

%
PIH

%
LMC

Polymerized
SiMix

%
DYS

BCMS1
BCMS2

3.17682
2.67889

42.18
49.95

O.10
O.10

O.10
O.10

45.85
35.85

1177
14.00

TABLE 9

Flexural Strength/Modulus of Exemplary Pll Systems

was used.

More specifically, in this example, functional studies have 50
been developed to determine the ability of filled SilMix to
stabilize bone in animal models. Pilot testing has begun on
extracted and in vivo rat femurs with a clean-cut fracture
introduced with a circular saw. SilMix or control bone cement

Flexural Test

Modulus

Strength (MPa.

GPa.

samples

Mean

St Dew

Mean

St Dew

in

Mold

Storage

BCMS1

22.26

2.78

1.58

O.O6

7

glass

24 hr?

PBS
is applied around the bone creating a 1-mm wide by 1-2 mm 55
thick band of composite material. The flexural strength of the BCMS2 25.77 1.53 1.63 O.O7 7 glass 24PBShr?
stabilized bones is then determined using four-point bend
testing. These initial studies have revealed that the more elas
In this example, the stress-strain curve for a neat dual
tic behavior of the SilMix is better suited to provide bone
stability than the relatively brittlebone cement (Simplex(RP). 60 chemical/light cure system having acetic acid was also deter
Six mice were sacrificed by authorized personnel. The mined as generally shown in panele of FIG. 4. The biomate
femora were then harvested from freshly sacrificed mice and rial composition comprised 93 wt % SilMix, 3 wt % acetic
stripped of Soft tissues. Femora were fractured using a hand acid, 3 wt % PIH, and 1 wt % camphorquinone. The dual
held circular saw. The fractured bones were repositioned and chemical/light cured silorane required about 5 minute's expo
stabilized with 50-70 uL of each SilMix resins around the 65 Sure to halogen light to polymerize. There was concern about
fracture site (n=6/SilMix formulation). The resin was cured the compatibility of the mechanical testing molds that were
either using a halogen lamp for 5 minutes (dual initiation developed for chemical cured materials. The compression
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cylinders are 1.2 cm long and 5 minute halogen light exposure
results in polymerization throughout the specimen.
Seven flexure beams were produced of a reasonable quality
(still some small flaws, mostly towardends of beam where not
directly affecting flexural testing). After 24 hours of dark
storage at room temperature, these were loaded at a rate of 3.7
mm/min as previously with bone cement.

5

34
It was also observed that the polymerization time and heat
generated is directly proportion to the speed of mixing as well
of material. Thinner samples polymerize slower than larger
samples. For example, 500 mg of material on glass slide
polymerizes in 15 minutes (passes GNT); whereas, a 100 mg
sample will take up to 45 minutes to polymerize. Also, the
speed of mixing generates more heat and aids in the polymer
ization reaction. The LMC catalyst was mixed in by hand.

TABLE 10

EXAMPLE 8

10

Flexural Strength - Dual Cured Silorane (unfilled).
beam

strength (MPa)

strain

modulus (MPa)

1
2
3
4
5
6
7
Mean

41.3
SO.4
74.1
57.5
42.5
55.6
40.7
51.7

7.3%
8.1%
9.8%
8.3%
8.2%
6.7%
6.9%
7.9%

1693.7
1908.1
2222.9
1724.0
1417.6
2627.7
1626.8
1888.7

Filled Chemically Initiated Silorane Exotherm
15

formulation. Bone cement mimic 5/6 contained a lower

amount of PIH and LMC. Due to the thinness of the samples,
it took approximately 30 minutes to complete cure to hard
ness (pass the one-1b GNT).

These values (Table 10) were comparable to previously
tested bone cement values. However, bone cement gave a
yield strength instead of maximum strength. The dual cured
specimens show a brittle fracture (FIG. 4).

TABLE 12
Cure time of three sillorane bone cement mimic formulations.
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Exotherms of Neat Chemically Initiated SilMix
(SM)
In this example, the chemically cured composition com
prised (A) co-monomer system SilMix (1:1 by weight of
PHEPSI and CYGEP), 99.89 wt %; (B) photoacid p-(octy
loxyphenyl)phenyliodonium hexafluoroantimonate, 0.04 wit
%, and (C) organometallic catalyst, Lamoreaux's catalyst,
0.07 wt %. As a control, the light initiated composition com
prised (A) co-monomer system SilMix (1:1 by weight of
PHEPSI and CYGEP), 95.85 wt %; and (B) light initiation
system comprising 3.0 wt % p-(octyloxyphenyl)phenyliodo

BCM1
BCM2
30 BCM3
BCM4
BCMS
BCM 6

40

45

Repetitions (n)

127.2 (6.2)
31.1 (3.8)

51.4 (4.6)
159.7 (70.4)

9
6

%

Max

Time

SM

PIH

LMC

CSM

DY5

(° C.)

(sec)

34.25
34.25
34.25
34.25
34.27
34.27

O.15
O.15
O.15
O.15
O.10
O.10

O.15
O.15
O.15
O.15
O.11
O.11

SS.84
SS.84
SS.84
SS.84
55.91
S5.91

9.61
9.61
9.61
9.61
9.61
9.61

34.9
35.3
29.5
32.7
27.0
27.0

128
156
247
243
88
96

(FIG. 7). There was some variability, likely due to difference
in mixing techniques, time to add the LMC, etc. Lower con
centrations of LMC catalyst resulted in a lower peak exo
therm and somewhat of a double peak in temperature. These
results were repeated, but only with two samples. Due to the
narrow range in temperatures (about 10°C.), the resolution of
our current thermocouple is inadequate (resulting in digitized
plots). Need to identify alternate temperature recording
device (RTD, thermistor, etc.) with greater resolution.
PROPHETIC EXAMPLE
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It will be appreciated that biocompatibility is an important
property for any biomaterial compositions of the present
invention. In addition to the MLO-A5 cell lines, the biocom

55

60

initiated silorane resins.

Cure time (s)

%

Overall, exotherm temperatures of the chemically cured

TABLE 11

Peak Exotherm (C.)

%

silorane bone cement mimics were well below 45° C. limit

nobenzoate.

Maximum exotherm measurements for photoinitiated and chemically

%

SM-SilMix; PIH phenyl iodonium salt; LMC Lamoreaux's catalyst; CSM-crushed

nium hexafluoroantimonate, about 1.0 wt % cam

Samples of approximately 120 mg were then placed on
thermocouples. Thermocouples had been previously pre
pared by taping a delrin washer on a glass slide onto which the
tip of the thermocouple was taped. The tip of the thermo
couple was centered approximately in the delrin washer. Pho
toinitiated SM samples were also tested using a similar man
ner. However, after mixing samples were placed in the delrin
washer/thermocouple set-up and irradiated for two minutes
with a dental curing lamp. Peak exotherm was collected from
the plots as well as cure time, defined as the time from mixing
to pass peak exotherm to reach half or max temperature
(Table 11). Sample temperature plots are shown in FIG.5 for
both the photo and chemical initiated SilMix.

%

35 SM (polymerized); DY5–yttrium silicate glass filler (unmodified)

phorquinone, and about 0.15 wt % ethyl 4-dimethylami

Chemically

Curing
Sample

EXAMPLE 7

Photoinitiated

In this example, two formulations were tested (Table 12,
FIG. 6). Bone cement mimics (BCM) 1/2 and 3/4 had the
same composition but were derived from different batches of

patibility of the compositions of the present invention can be
assessed using, for example, MSCs (mesenchymal stem cells
from bone marrow), L929 (fibroblast like cells), and HUVEC
(human umbilical vein endothelial cells). Further, to deter
mine the potential of the silorane compositions to induce
mineralization as another measure of its biocompatibility
with bone, differentiation assays, such as alkaline-phos
phatase, and mineralization assays, Such as alizarin red and
von Kossa staining, may be performed on the MLO-A5 cell
line. These tests will determine the effect of the polymer on
the ability of cells to proliferate, differentiate, and form min
eralized matrix.
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Small Animal (Rat) Model: Pull-out strength ex vivo:
These studies will be conducted according to published meth
ods which have been used as an in vivo model for implants.

US 9, 186,302 B2
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Male Sprague-Dawley rats (approximately 6 months old) will
be sacrificed and kept in-80°C. freezer. The femora will be
excised. A 2 mm hole will be drilled into the intercondylar
notch with a Dremel drill bit to penetrate the subchondral
cortical bone and gain access to the femoral intramedullary
canal. The marrow cavity will be disrupted by inserting a
threaded hand drill proximally through the entirelength of the
diaphysis to approximately the level of the lesser trochanter.
A guide implant will be placed into the ablated cavity to
ensure that the canal will be an appropriate size to accommo
date the definitive implant. The cavity will then be flushed

10

with 10 mL of sterile saline for removal of loose marrow

contents. Following irrigation, bone cement (chemically
cured silorane and fillers (bone cement mimic) or commercial
bone cement) will be introduced into the intramedullary canal
with a root canal filler and then a titanium implant, 22 mm
long and 1.5 mm diameter, will be implanted in a retrograde
manner. The femora implanted with titanium rods fixed with
bone cement mimic or commercial bone cement will be kept
24 hours and tested biomechanically. The 2-4 mm of distal
rod (implant) will be exposed; proximal half of femur will be
embedded in dental acrylic in a holder. The holder is a lower
part of a 15 mL centrifuge tube which is cut at mark-line 3 mL
and can be filled 3 g of dental acrylic and is attached an eye
hook at bottom. The exposed implant will be gripped with a
drill chuck and Shooks will be placed at lower end of the
specimen to keep coaxial alignment of the implant with the
direction of force. The pullout test will be conducted at a
displacement rate of 0.25 mm/min to failure with the force
(N). The values will be calculated by dividing the force at the
point of failure by the surface area of the implant in the femur.

36
sule and skin will be sutured with 4-0 nylon. Buprenex, 0.01
0.05 mg/kg and Atipamezole, 0.1-1 mg/kg will be adminis
tered intraperitoneally to the rat immediately post operation.
The animal will be allowed to fully recover in a separate cage
on the warming pad and will be allowed activity ad libitum.
Post-op Analysis: The inflammatory response of incision
and movement of operated limb will be monitored every day.
Microcomputed tomography (MicroCT) and X-ray will be
taken at weeks 1, 4, and 8 weeks post Surgery. Animals will be
euthanized by CO asphyxiation at 1 (to examine for any
inflammatory reaction) and 8 weeks (to examine for osseoin
tegration) post Surgery. The femurs for mechanical testing
will be harvested, denuded of soft tissue, and frozen at -20°
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C. The procedure of mechanical test could be seen above. The
femurs for histology will be placed in 10% neutral buffered
formalin.

Tissue Preparation, Histology, and Histomorphometry:
After placement and sacrifice, bones will be fixed in neutral
buffered formalin, decalcified and embedded for frozen sec
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tions by standard techniques. Serial sections will be cut and
stained with Hematoxylin and Eosin (H&E) or Goldner's
trichrome using standard techniques. Staining for both TRAP
and alkaline phosphatase can be performed. Undecalcified
methacrylate embedded sections will also be stained by the
Von Kossa procedure as described previously for determina
tion of the mineralized bone volume by histomorphometry.
Histomorphometric Analysis: Histomorphometric analy
sis will be performed on long bones using a Nikon E800
microscope with live video image capabilities that is inter
faced with the Osteomeasure bone histomorphometry soft
ware. The parameters to be measured from H&E and/or Gold

This result will determine if the silorane based bone cement

ner's trichrome stained sections include trabecular and

provides adequate mechanical Support.
Osteointegration of the silorane bone cement in vivo: After
ex vivo testing, the osseointegration with the silorane bone
cement or PMMA bone cement will be assessed. The general
biological response, including inflammation and bone min

numbers per mm bone surface. TRAP stained sections will be
used for determination of the number of osteoclasts per mm

cortical bone Volume, osteoid seam thickness, and osteoblast
35

bone surface. Von Kossa stained sections will be used to
measure the volume of mineralized bone which will be

eralization, must also be characterized for the silorane bone

cements. The samples will be split into two parts: pull-out
strength and histological analysis.
Implant Placement: Male Sprague-Dawley rats (approxi
mately 6 months old) will be placed under general anesthesia
via isofluorane inhalation (3-4% for induction), ketamine/
dex-medetomidine (75/0.5 mg/kg body weight; IP) for main
tenance. The animal will be weighed and the both legs will be
shaved with a standard clipper and disinfected with povidone/
iodine Solution. Animals will be placed on a warming pad
during Surgery as provided in the animal facility (recirculat
ing water heating pad). All procedures will be performed
under aseptic conditions. A 1 cm lateral parapatellar incision
will be made to expose the knee joint. The patella will be
retracted medially with the knee extended. The knee will be
slowly flexed to expose the intercondylar notch. A 2 mm hole
will be drilled into the intercondylar notch with a Dremel drill
bit to penetrate the subchondral cortical bone and gain access
to the femoral intramedullary canal. The marrow cavity will
be disrupted by inserting a threaded hand drill proximally
through the entire length of the diaphysis to approximately
the level of the lesser trochanter. A guide implant will be
placed into the ablated cavity to ensure that the canal will be
an appropriate size to accommodate the definitive implant.
The cavity will then be flushed with 10 mL of sterilesaline for
removal of loose marrow contents. Following irrigation, bone
cement (chemically cured silorane and fillers or commercial
bone cement) will be introduced into the intramedullary
canal, and then a titanium implant, 22 mm long and 1.5 mm
diameter, will be implanted in a retrograde manner. The cap
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expressed as a percentage of the total bone Volume (i.e.,
including osteoid). Three non-consecutive sections (100 um
apart) from each specimen will be used for the histomorpho
metricanalyses described above and these measurements will
be performed by an individual who is without knowledge of
the sample identities. Values will be expressed as the
meantstandard error. Examination for wear debris particles
in the surrounding tissue will be performed.
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From the foregoing it will be seen that this invention is one 30
well adapted to attain all ends and objectives herein-above set
forth, together with the other advantages which are obvious
and which are inherent to the invention. Since many possible
embodiments may be made of the invention without depart
ing from the scope thereof, it is to be understood that all 35
matters herein set forth or shown in the accompanying figures
are to be interpreted as illustrative, and not in a limiting sense.
While specific embodiments have been shown and discussed,
various modifications may of course be made, and the inven
tion is not limited to the specific forms or arrangement of parts 40
and steps described herein, except insofar as Such limitations
are included in the following claims. Further, it will be under
stood that certain features and subcombinations are of utility
and may be employed without reference to other features and
subcombinations. This is contemplated by and is within the 45
Scope of the claims.
We claim:

1. A biomaterial composition comprising:
a polymerizable silorane monomer, and
a curing system selected from the group consisting of a
chemical curing system and a dual chemical/light curing

50

system,

wherein the curing system comprises a rhodium-based or
platinum-based organometallic catalyst, and wherein
said silorane monomer comprises a mixture of 2.4.6.8tetramethyl-2,4,6,8-tetrakis-2-(7-Oxabicyclo4.1.0
hept-3-yl)ethyl-1,3,5,7-tetraoxa-2,4,6,8-tetrasilacy
clooxtane (CYGEP) and methylbis 2-(7-Oxabicyclo
4.1.0]hept-3-yl)ethylphenylsilane (PHEPSI).
2. The biomaterial composition of claim 1 wherein said
curing system comprises an organometallic catalyst selected
from the group consisting of Lamoreaux's catalyst, Wilkin
son’s catalysts, Speier's catalyst, and Karstedt's catalyst, or
mixtures thereof.

3. The biomaterial composition of claim 1 wherein said
chemical curing system further comprises a photoacid.
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4. The biomaterial composition of claim 3, wherein said
photoacid is a phenyliodonium compound.
5. The biomaterial composition of claim 4 wherein said
photoacid is selected from the group consisting of (4-n-octy
loxyphenyl)phenyliodonium hexafluoroantimonate, 4-(2hydroxy-tetradecyloxyphenyl)phenyliodonium hexafluoro
antimonate,
4-1-methylethyl)-phenyl(4-methylphenyl)
iodonium tetrakis(pentafluorophenyl)borate(1-), and
combinations thereof.

6. The biomaterial composition of claim 1 wherein said
curing system is a dual chemical/light curing system, wherein
said dual chemical/light curing system additionally com
prises an acid selected from the group consisting of a Bron
sted acid, Lewis acid, and a Superacid, and mixtures thereof.
7. The biomaterial composition of claim 1 wherein said
curing system is a dual chemical/light curing system addi
tionally comprises an acid selected from the group consisting
of acetic acid, phosphoric acid, Sulfuric acid, hydrobromic
acid, hydroiodic acid, trichloroacetic acid, trifluoroacetic
acid, p-toluenesulfonic acid, boron trifluoride, aluminium
chloride, tin (IV) chloride, titanium chloride, pentafluoro
proprionic acid, triflic acid, hexafluorophosphoric acid, ethyl
triflate, potassium t-butoxide, and mixtures thereof.
8. The biomaterial composition of claim 7 wherein said
dual chemical/light curing system further comprises a photo
sensitizer.

9. The biomaterial composition of claim 8 wherein said
photosensitizer is a diketone.
10. The biomaterial composition of claim 7 wherein said
dual chemical/light curing system further comprises an elec
tron donor compound in which said electron donor is a Sub
stituted amine.

11. The biomaterial composition of claim 7 wherein said
dual chemical/light curing system comprises acetic acid,
p-(octyloxyphenyl)phenyliodonium hexafluoroantimonate,
and camphorquinone.
12. The biomaterial composition of claim 11 further com
prising a filler.
13. The biomaterial composition of claim 12 further com
prising a tetraoxaspiro5.5undecane.
14. The biomaterial composition of claim 1 wherein said
curing system is a dual chemical/light curing system, wherein
said dual chemical/light curing system comprises a rhodium
or platinum-based organometallic catalyst and a light initia
tion system having a photoacid, photosensitizer, and an elec
tron donor.

15. The biomaterial composition of claim 14 wherein
said organometallic catalyst is selected from the group
consisting of Lamoreaux's catalyst, Wilkinson's cata
lysts, Speier's catalyst, and Karstedt's catalyst;
said photoacid is a phenyliodonium compound;
said photosensitizer is a diketone; and
said electron donor is a Substituted amine.

55

16. The biomaterial composition of claim 14 wherein
said organometallic catalyst comprises Lamoreaux's cata
lyst;
said photoacid comprises p-(octyloxyphenyl)phenyliodo
nium hexafluoroantimonate;
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said photosensitizer comprises camphorquinone; and
said electron donor comprises ethyl p-dimethylaminoben
ZOate.
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17. The biomaterial composition of claim 16 further com
prising a filler.
18. The biomaterial composition of claim 17 further com
prising a tetraoxaspiro5.5undecane.
19. The biomaterial composition of claim 1 further com
prising one or more tetraoxaspiro5.5undecanes.
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20. The biomaterial composition of claim 19, wherein said
tetraoxaspiro5.5undecane is selected from the group con
sisting of a 2.4.8.10-tetraoxaspiro5.5undecane or a 1.5.7.
11- tetraoxaspiro5.5undecane.
21. The biomaterial composition of claim 19 wherein said
tetraoxaspiro5.5undecane is selected from Formulas A1
and A2

R

O

O

R3

(A1)

10

(A2)

15

six X y O
O

R1 O

O

O

R3

six X).
O

merizable silorane monomer.

25. The biomaterial composition of claim 1 comprising

O

about 30 to 60 wt % silorane monomers; about 1 to 50 wt %

wherein RandR are independently is alkyl, aryl, aralkyl,
or hydrogen; and
wherein R and Rare independently alkenoxy, alkenoxy
alkyl, or silicon-containing moiety selected from alkyl
silyl, arylsilyl, arylalkylsilyl, alloxysilyl, aryloxysilyl,
arylalkoxysilyl, alkylsiloxy, arylsiloxy, arylalkylsiloxy,
alkoxysiloxy, aryloxysiloxy, arylalkoxysiloxy, alkylsi
lylalkyl, arylsilylalkyl, arylalkysilylalkyl, alkoxysilyla
lkyl, aryloxysilylalkyl, arylalkoxysilylalkyl, alkylsi
loxyalkyl, arylsiloxyalkyl, arylalkylsiloxyalkyl,
alkoxysiloxyalkyl, aryloxysiloxyalkyl, arylalkoxysi
loxyalkyl, alkylsilylalkoxy, arylsilylalkoxy, arylalkylsi
lylalkoxy, alkoxysilylalkoxy, aryloxysilylalkoxy aryla
lkyloxysilylalkoxy,
alkylsiloxyalkoxy,
arylsiloxyalkoxy, arylalkylsiloxyalkoxy, alkoxysiloxy
alkoxy, aryloxysiloxyalkoxy, and arylalkoxysiloxy
alkoxy.
22. The biomaterial composition of claim 19, wherein said
tetraoxaspiro5.5undecane is selected from the group con
sisting of 3,9-diethyl-3.9-bis(allyloxymethyl)-1.5.7.11-tet
raoxaspiro5.5undecane (DEBAOM-1,5,7,11-TOSU); 3.9bis(3-trimethylsilylpropyl)-1.5.7.11-tetraoxaspiro5.5
undecane

(BTMSP-

1,5,7,11-TOSU);
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(BAOM-2,4,8,10-TOSU); 3.9-bis(2-trimethylsilylethyl)-2,3,
8,10-tetraoxaspiro5.5undecane (BTMSE-2,4,8,10-TOSU):
5,5-diethyl-19-oxadispiro 1,3-dioxane-2,2'-1,3-dioxane-5'.
4"-bicyclo[4.1.0]heptane (DECHE-1,5,7,11-TOSU); 3.9diethyl-3.9-bis(3-trimethylsilylpropyloxymethyl)-1.5.7.11
tetraoxaspiro5.5-undecane
(DEBTMSPOM-1,5,7,11
TOSU); (9-allyloxymethyl-9-ethyl-1,5,7,11-tetraoxaspero
5.5undec-3-ylmethyl)-dimethylphenyl-silane (AOME
TOSU-MDMPS); and
methyl 2-(7-Oxabicyclo[4.1.0 hept-3-yl)ethyl-pheynl3
(3.9.9-triethyl-1.5.7.11-tetraoxaspiro5.5undec-3-yl
methoxy)propylsilane (MOB-HEP-TETOSU-MOPS).
23. The biomaterial composition of claim 1 further com
prising a filler.
24. The biomaterial composition of claim 1 further com
prising a pre-polymerized polymer derived from said poly

3,9-bis

(allyloxymethyl)-2,4,8,10-tetraoxaspiro5.5undecane
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of a pre-polymerized polymer derived from the silorane
monomers; and about 0.05 to 5 wt % of the chemical curing
system or dual chemical/light curing system, and wherein
said curing system comprises acetic acid or Lamoreaux's
catalyst.
26. The biomaterial composition of claim 25 further com
prising about 5 to 50 wt % of a filler.
27. The biomaterial composition of claim 1 wherein said
composition after polymerization exhibits a peak exotherm
below about 30 °C.
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28. The biomaterial composition of claim 1 wherein said
composition after polymerization exhibits a flexural strength
of about 22 to 50 MPa.

29. The biomaterial composition of claim 1 wherein said
composition after polymerization exhibits a flexural modulus
about 1.5 to 3.5 GPa.
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30. The biomaterial composition of claim 1 further com
prising a heat-sensitive antimicrobial or growth factor that is
Stable at about 25 to 30 °C.
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31. The biomaterial composition of claim 1 further com
prising a growth factor selected from the group consisting of
TGFB1, TGFB2, TGFB3, BMP-2, BMP-3, BMP-4, BMP-5,
BMP-6, BMP-7, BMP-8, BMP-9, CDMP-1, CDMP-2, or
CDMP-3.

